CA1339480C - Antiparasitic agents and process for their preparation - Google Patents
Antiparasitic agents and process for their preparationInfo
- Publication number
- CA1339480C CA1339480C CA000514661A CA514661A CA1339480C CA 1339480 C CA1339480 C CA 1339480C CA 000514661 A CA000514661 A CA 000514661A CA 514661 A CA514661 A CA 514661A CA 1339480 C CA1339480 C CA 1339480C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alpha
- double bond
- group
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
- C12P19/62—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/465—Streptomyces
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/886—Streptomyces
Abstract
The invention provides novel compounds having the formula:
(see fig. I) wherein the broken line at the 22-23 position represents an optional double bond and wherein R1 is H or OH and the double bond is absent, or, the double bond is present and R1 is absent; R2 is an alpha-branched C3-C8 alkyl group, an alpha-branched C3-C8 alkenyl group, an alpha-branched C3-C8 alkoxy-alkyl group, an alpha-branched C3-C8 alkylthioalkyl group; a C5-C8 cycloalkylalkyl group wherein the alkyl group is an alpha-branched C2-C5 alkyl group; a C3-C8 cycloalkyl or C5-C8 cycloalkenyl group, either of which may optionally be substituted by methylene or one or more C1-C4 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C1-C4 alkyl groups or halo atoms; R3 is hydrogen or methyl; R4 is H or 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy, with the proviso that when R2 is alkyl it is not isopropyl or sec-butyl; and when R4 is H, R1 is OH, and the double bond is absent, R2 is not 2-buten-2-yl, 2-pentene-2-yl or 4-methyl-2-pentene-2-yl. The compounds are broad spectrum antiparasitic agents having utility as anthelmintics, ectoparasiticides, insecticides and acaricides. The invention also provides a process for producing the novel avermectin and milbemycin derivatives by adding a carboxylic acid or derivative thereof to a fermentation of an avermectin or milbemycin producing organism.
(see fig. I) wherein the broken line at the 22-23 position represents an optional double bond and wherein R1 is H or OH and the double bond is absent, or, the double bond is present and R1 is absent; R2 is an alpha-branched C3-C8 alkyl group, an alpha-branched C3-C8 alkenyl group, an alpha-branched C3-C8 alkoxy-alkyl group, an alpha-branched C3-C8 alkylthioalkyl group; a C5-C8 cycloalkylalkyl group wherein the alkyl group is an alpha-branched C2-C5 alkyl group; a C3-C8 cycloalkyl or C5-C8 cycloalkenyl group, either of which may optionally be substituted by methylene or one or more C1-C4 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C1-C4 alkyl groups or halo atoms; R3 is hydrogen or methyl; R4 is H or 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy, with the proviso that when R2 is alkyl it is not isopropyl or sec-butyl; and when R4 is H, R1 is OH, and the double bond is absent, R2 is not 2-buten-2-yl, 2-pentene-2-yl or 4-methyl-2-pentene-2-yl. The compounds are broad spectrum antiparasitic agents having utility as anthelmintics, ectoparasiticides, insecticides and acaricides. The invention also provides a process for producing the novel avermectin and milbemycin derivatives by adding a carboxylic acid or derivative thereof to a fermentation of an avermectin or milbemycin producing organism.
Description
DESCRIPTION
This invention relates to antiparasitic agents and in particular to compounds related to the avermectins and milbemycins but having a novel substituent group at the 25-position and to a process for their preparation.
The avermectins are a group of broad spectrum antiparasitic agents referred to previously as the C-076 compounds. They are produced by fermenting a strain of the microorganism Streptomyces avermitilis ATCC 31267, 31271 or 31272 under aerobic conditions in an aqueous nutrient medium containing inorganic salts and assimilable sources of carbon and nitrogen.
The morphological and cultural properties of the strains ATCC
31267, 31271 and 31272 are described in detail in British Patent Specification No. 1573955 which also describes the isolation and the chemical structure of the eight individual components which make up the C-076 complex. The milbemycins are structurally related macrolide antibiotics lacking the sugar residues at the 13-position. They are produced by fermentation, for example as described in British Patent Specification No. 1390336 and European Patent Application Publication No. 0170006.
We have now discovered that by adding certain specified carboxylic acids, or derivatives thereof, to the fermentation of an avermectin producing organism it is possible to obtain novel compounds, related to the avermectins but having an unnatural substituent group at the 25-position in place of the isopropyl or sec-butyl group which is normally present. The novel compounds are highly active antiparasitic agents having particular utility 13394~0 as anthelmintics, ectoparasiticides, insecticides and acaricides.
Thus, according to one aspect of the invention there i8 provided a process for producing a novel avermectin derivative having an unnatural ~ub~tituent group at the 25-position which comprises ~;ng an assimilable carboxylic acid, or a salt, ester or amide thereof or oxidative precursor therefor, to a fermentation of an avermectin producing organi~m, and isolating the novel avermectin derivative.
Co"~e"tional chemical transformation reactions can be used to prepare further derivatives from these compounds.
Thus, according to a further aspect of the invention there are provided compounds having the formula:
CH3 2~ ~ CH3 R4 ~ ~ R2 CH3/~
~ 0~,0 (I) I ¦ OHl O ~ CH3 OR
wherein the broken line at the 22-23 position represents an optional double bond and wherein R1 i~ H or OH and the double bond is absent, or, the double bond i8 present and R1 is absent;
~' R2 is an alpha-branched C3-C8 alkyl group, an alpha-branched C3-C8 alkenyl group, an alpha-branched C3-C8 alkoxy-alkyl group, an alpha-branched C3-C8 alkylthioalkyl group; a C5-C8 cycloalkylalkyl group wherein the alkyl group is an alpha-br~ncheA C2-C5 alkyl group; a C3-C8 cycloalkyl or C5-C8 cycloalkenyl group, either of which may optionally be substituted by methylene or one or more Cl-C4 alkyl group~ or halo atom~; or a 3 to 6 membered oxygen or sulphur cont~;n;ng heterocyclic ring which may be ~aturated, or fully or partially un~aturated and which may optionally be sub~tituted by one or more Cl-C4 alkyl groups or halo atoms;
R3 is hydrogen or methyl;
- 2a -1339~0 R is H or a 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy group of the formula:
c~3 CH3 H0~ 0--~~--with the proviso that when R2 is alkyl it is not isopropyl or sec-butyl; and when R4 is H, Rl is OH, and the double bond is absent, R2 is not 2-buten-2-yl, 2-penten-2-yl or 4-methyl-2-penten-2-yl.
In the above definition, alkyl groups cont~ning 3 or more carbon atoms may be straignt or branched chain. Halo means fluoro, chloro, bromo or iodo. Alpha-branched means that the carbon atom attached to the 25-ring position is a secondary carbon atom linked to two further carbon atoms. When R2 is alkyl of 5 or more carbon atoms, the remainder of the alkyl chain may be straight or branched chain.
Preferred compounds of the formula I are those wherein R4 is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy. Also preferred are compounds of the formula I wherein R is a C5 or C6 cycloalkyl or cycloalkenyl group which may optionally be substituted by one or more Cl-C4 alkyl groups, cyclopentyl being particularly preferred. In another group of preferred compounds R is cyclobutyl. In a further group of preferred compounds R2 is a 5 or 6 membered oxygen or sulphur containing heterocyclic ring, particularly a 3-thienyl or 3-furyl ring, which may optionally be substituted by one or more Cl-C4 alkyl groups or halogen atoms.
In a yet further group of preferred compounds, R is a C3-C8 alkylthioalkyl group, particularly a l-methylthioethyl group.
In accordance with the invention the compounds of formula I
wherein R is OH and the double bond is absent or wherein the double bond is ?resent and R is absent and R is 4'-(alpha-r-oleandrosyl)-alpha-L-oleandrosyloxy are prepared by fermenting an avermectin producing organism, such as a strain of the organism Streptomyces avermitilis ATCC 31267, 31271 or 31272, in the presence of the appropriate carboxylic acid of the formula R CO2H, wherein R is as previously defined, or a salt, ester, or amide thereof or oxidative precursor therefor. The acid is added to the fermentation either at the time of inoculation or at intervals during the fermentation. Production of the compounds of formula (I) may be monitored by removing samples from the fermentation, extracting with an organic solvent and following the appearance of the compound of formula (I) by chromatography, for example using high pressure liquid chromatography. Incubation is continued until the yield of the compound of formula (I~ has been r~; ;.sed, generally for a period of from 4 to 6 days.
A preferred level of each addition of the carboxylic acid or derivative thereof is between 0.05 and 1.0 grams per litre. The best yields of the compounds of formula (I) are obtained by gradually adding the acid to the fermentation, for example by daily additions of the acid or derivative thereof over a period of several days. The acid is preferably added as a salt, such as the sodium or ammonium salt, but may be added as an ester, such as the methyl or ethyl ester or as an amide. Alternative substrates which may be used in the fermentation are derivatives which are oxidative precursors for the carboxylic acids; thus, for example suitable substrates would be aminoacids of the formula R CH(NH2)CO2H, glyoxylic acids of tlle formula R COCO2H, methylamine derivatives of the formula R CH2NH2, substituted lower alkanoic acids of the formula R (CH2) CO2H wherein n is 2, 4 or 6, methanol derivatives of the formula R CH~OH or aldehydes of the formula R CHO, wherein R2 is as previously defined. The media used for the fermentation may be a conventional complex media containing assimilable sources of carbon, nitrogen and other trace elements. However we have found that for better results a strain of the organism derived from Streptomyces avermitilis ATCC 31271 which gives improved yields of a compound of formula I when 1339~80 cultured in a semi-defined medium may be used and this has the advantage that crude solvent extracts contain significantly less unwanted materia' which greatly simplifies the subsequent isolation and purification stages. Such a strain has been deposited with the National Collection of Industrial Bacteria (NCIB) on l9th July, 1985 under the accession number NCIB 12121.
The morphological and cultural characteristics of this strain are otherwise generally as described in British Patent specification no. 1573955 for strain ATCC 31267.
After fermentation for a period of several days at a temperature preferably in the range of from 24 to 33~C,the fermentation broth is centrifuged or filtered and the mycelial cake is extracted with acetone or methanol. The solvent extract is concentrated and the desired product is then extracted into a water-immiscible organic solvent, such as methylene chloride, ethyl acetate, chloroform, butanol or methyl isobutyl ketone. The solvent extract is concentrated and the crude product containing the compounds of formula (I) is further purified as necessary by chromatography, for example using preparative reverse phase, high pressure liquid chromatography.
The product is generally obtained as a mixture of the compounds of formula (I) wherein R is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy, R is OH and the double bond absent or R
is absent and the double bond is present and wherein R is H or CH3; however the proportions can vary depending on the particular carboxylic acid employed and the conditions used.
We have found that a broad range of carboxylic acids as defined by R CO2H may be added to the fermentation to yield avermectins having a novel substituent group at the 25-position.
Examples of particular acids which may be employed include ~he following:
This invention relates to antiparasitic agents and in particular to compounds related to the avermectins and milbemycins but having a novel substituent group at the 25-position and to a process for their preparation.
The avermectins are a group of broad spectrum antiparasitic agents referred to previously as the C-076 compounds. They are produced by fermenting a strain of the microorganism Streptomyces avermitilis ATCC 31267, 31271 or 31272 under aerobic conditions in an aqueous nutrient medium containing inorganic salts and assimilable sources of carbon and nitrogen.
The morphological and cultural properties of the strains ATCC
31267, 31271 and 31272 are described in detail in British Patent Specification No. 1573955 which also describes the isolation and the chemical structure of the eight individual components which make up the C-076 complex. The milbemycins are structurally related macrolide antibiotics lacking the sugar residues at the 13-position. They are produced by fermentation, for example as described in British Patent Specification No. 1390336 and European Patent Application Publication No. 0170006.
We have now discovered that by adding certain specified carboxylic acids, or derivatives thereof, to the fermentation of an avermectin producing organism it is possible to obtain novel compounds, related to the avermectins but having an unnatural substituent group at the 25-position in place of the isopropyl or sec-butyl group which is normally present. The novel compounds are highly active antiparasitic agents having particular utility 13394~0 as anthelmintics, ectoparasiticides, insecticides and acaricides.
Thus, according to one aspect of the invention there i8 provided a process for producing a novel avermectin derivative having an unnatural ~ub~tituent group at the 25-position which comprises ~;ng an assimilable carboxylic acid, or a salt, ester or amide thereof or oxidative precursor therefor, to a fermentation of an avermectin producing organi~m, and isolating the novel avermectin derivative.
Co"~e"tional chemical transformation reactions can be used to prepare further derivatives from these compounds.
Thus, according to a further aspect of the invention there are provided compounds having the formula:
CH3 2~ ~ CH3 R4 ~ ~ R2 CH3/~
~ 0~,0 (I) I ¦ OHl O ~ CH3 OR
wherein the broken line at the 22-23 position represents an optional double bond and wherein R1 i~ H or OH and the double bond is absent, or, the double bond i8 present and R1 is absent;
~' R2 is an alpha-branched C3-C8 alkyl group, an alpha-branched C3-C8 alkenyl group, an alpha-branched C3-C8 alkoxy-alkyl group, an alpha-branched C3-C8 alkylthioalkyl group; a C5-C8 cycloalkylalkyl group wherein the alkyl group is an alpha-br~ncheA C2-C5 alkyl group; a C3-C8 cycloalkyl or C5-C8 cycloalkenyl group, either of which may optionally be substituted by methylene or one or more Cl-C4 alkyl group~ or halo atom~; or a 3 to 6 membered oxygen or sulphur cont~;n;ng heterocyclic ring which may be ~aturated, or fully or partially un~aturated and which may optionally be sub~tituted by one or more Cl-C4 alkyl groups or halo atoms;
R3 is hydrogen or methyl;
- 2a -1339~0 R is H or a 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy group of the formula:
c~3 CH3 H0~ 0--~~--with the proviso that when R2 is alkyl it is not isopropyl or sec-butyl; and when R4 is H, Rl is OH, and the double bond is absent, R2 is not 2-buten-2-yl, 2-penten-2-yl or 4-methyl-2-penten-2-yl.
In the above definition, alkyl groups cont~ning 3 or more carbon atoms may be straignt or branched chain. Halo means fluoro, chloro, bromo or iodo. Alpha-branched means that the carbon atom attached to the 25-ring position is a secondary carbon atom linked to two further carbon atoms. When R2 is alkyl of 5 or more carbon atoms, the remainder of the alkyl chain may be straight or branched chain.
Preferred compounds of the formula I are those wherein R4 is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy. Also preferred are compounds of the formula I wherein R is a C5 or C6 cycloalkyl or cycloalkenyl group which may optionally be substituted by one or more Cl-C4 alkyl groups, cyclopentyl being particularly preferred. In another group of preferred compounds R is cyclobutyl. In a further group of preferred compounds R2 is a 5 or 6 membered oxygen or sulphur containing heterocyclic ring, particularly a 3-thienyl or 3-furyl ring, which may optionally be substituted by one or more Cl-C4 alkyl groups or halogen atoms.
In a yet further group of preferred compounds, R is a C3-C8 alkylthioalkyl group, particularly a l-methylthioethyl group.
In accordance with the invention the compounds of formula I
wherein R is OH and the double bond is absent or wherein the double bond is ?resent and R is absent and R is 4'-(alpha-r-oleandrosyl)-alpha-L-oleandrosyloxy are prepared by fermenting an avermectin producing organism, such as a strain of the organism Streptomyces avermitilis ATCC 31267, 31271 or 31272, in the presence of the appropriate carboxylic acid of the formula R CO2H, wherein R is as previously defined, or a salt, ester, or amide thereof or oxidative precursor therefor. The acid is added to the fermentation either at the time of inoculation or at intervals during the fermentation. Production of the compounds of formula (I) may be monitored by removing samples from the fermentation, extracting with an organic solvent and following the appearance of the compound of formula (I) by chromatography, for example using high pressure liquid chromatography. Incubation is continued until the yield of the compound of formula (I~ has been r~; ;.sed, generally for a period of from 4 to 6 days.
A preferred level of each addition of the carboxylic acid or derivative thereof is between 0.05 and 1.0 grams per litre. The best yields of the compounds of formula (I) are obtained by gradually adding the acid to the fermentation, for example by daily additions of the acid or derivative thereof over a period of several days. The acid is preferably added as a salt, such as the sodium or ammonium salt, but may be added as an ester, such as the methyl or ethyl ester or as an amide. Alternative substrates which may be used in the fermentation are derivatives which are oxidative precursors for the carboxylic acids; thus, for example suitable substrates would be aminoacids of the formula R CH(NH2)CO2H, glyoxylic acids of tlle formula R COCO2H, methylamine derivatives of the formula R CH2NH2, substituted lower alkanoic acids of the formula R (CH2) CO2H wherein n is 2, 4 or 6, methanol derivatives of the formula R CH~OH or aldehydes of the formula R CHO, wherein R2 is as previously defined. The media used for the fermentation may be a conventional complex media containing assimilable sources of carbon, nitrogen and other trace elements. However we have found that for better results a strain of the organism derived from Streptomyces avermitilis ATCC 31271 which gives improved yields of a compound of formula I when 1339~80 cultured in a semi-defined medium may be used and this has the advantage that crude solvent extracts contain significantly less unwanted materia' which greatly simplifies the subsequent isolation and purification stages. Such a strain has been deposited with the National Collection of Industrial Bacteria (NCIB) on l9th July, 1985 under the accession number NCIB 12121.
The morphological and cultural characteristics of this strain are otherwise generally as described in British Patent specification no. 1573955 for strain ATCC 31267.
After fermentation for a period of several days at a temperature preferably in the range of from 24 to 33~C,the fermentation broth is centrifuged or filtered and the mycelial cake is extracted with acetone or methanol. The solvent extract is concentrated and the desired product is then extracted into a water-immiscible organic solvent, such as methylene chloride, ethyl acetate, chloroform, butanol or methyl isobutyl ketone. The solvent extract is concentrated and the crude product containing the compounds of formula (I) is further purified as necessary by chromatography, for example using preparative reverse phase, high pressure liquid chromatography.
The product is generally obtained as a mixture of the compounds of formula (I) wherein R is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy, R is OH and the double bond absent or R
is absent and the double bond is present and wherein R is H or CH3; however the proportions can vary depending on the particular carboxylic acid employed and the conditions used.
We have found that a broad range of carboxylic acids as defined by R CO2H may be added to the fermentation to yield avermectins having a novel substituent group at the 25-position.
Examples of particular acids which may be employed include ~he following:
2-methylvaleric acid 2-methylpent-4-enoic acid 2-methylthiopropionic acid 2-cyclopropyl propionic acid cyclobutane carboxylic acid 13~g480 cyclopentane carboxylic acid cyclohexane carboxylic acid cycloheptane carboxylic acid 2-methylcyclopropane carboxylic acid 3-cyclohexene-1-carboxylic acid and thiophene-3-carboxylic acid In one particular and preferred aspect of the invention, the fermentation is performed in the presence of cyclopentane carboxylic acid sodium salt to yield predominantly the compound of formula (I) wherein R is OH, the double bond is absent, R is cyclopentyl, R is CH3 and R is 4'-(alpha-L-oleandrosyl)-alpha-4-oleandrosyloxy.
In another preferred aspect of the invention, the fermentation is performed in the presence of thiophene-3-carboxylic acid sodium salt to yield predominantly the compound of formula (I) wherein Rl is OH, the double bond i3 absent, R is thien-3-yl, R is CH3 and R is 4'-(alpha-L-oleandrosyl)-alpha-4-oleandrosyloxy.
In a further preferred aspect of the invention the fermentation is performed in the presence of 2-methylthiopropionic acid sodium salt to yield predominantly the compound of formula (I) wherein R is OH, the double bond is absent, R is l-methylthioethyl, R3 is CH and R is 4'-(alpha-L-oleandrosyl)-alpha-4-oleandrosyloxy.
Compounds of the formula (I) wherein the double bond is present and R is absent may alternatively be prepared from the corresponding compound of formula (I) wherein R is OH and the double bond is absent by a dehydration reaction. The reaction is performed by first selectively protecting the hydroxyl groups at the 5 and 4" posi-tions, e.g. as the t-butyldimethylsilyloxy acetyl derivative, then reacting with a substituted thiocarbonyl halide, such as (4-methylphenoxy)thiocarbonyl chloride, followed by heating in a high boiling point solvent, e.g. trichlorobenzene, to effect the dehydration. The product is finally deprotected to give the unsaturated compound. These steps together with appropriate reagents and reaction conditions are described in United States patent 4328335.
The compounds of formula I wherein R3 is H may also be prepared from the corresponding compounds wherein R is CH3 by demethylat~on. This reaction is achieved by treating the 5-methoxy compound, or a suitably protected derivative thereof, with mercuric acetate and hydrolysing the resulting 3-acetoxy enol ether with dilute acid to give the 5-keto compound. This is then reduced using, for example, sodium borohydride to yield the 5-hydroxy derivative. Appropriate reagents and reaction conditions for these steps are described in United States patent 4423209.
The compounds of formula I wherein R is H and the double bond is absent can be prepared from the corresponding compound wherein the double bond is present and Rl is absent, by selective catalytic hydrogenation using an appropriate catalyst. For example the reduction may be achieved using tris(triphenyl-phosphine)rhodium (I) chloride as described in European patent application publication no. 0001689.
The compounds of formula (I) wherein R is H are prepared from the corresponding compounds wherein R is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy by removing the 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrose group by mild hydrolysis with an acid in an aqueous organic solvent to yield the aglycone having a hydroxy group at the 13-position; this is then halogenated, for example by reaction with a benzene sulphonyl halide, to yield the 13-deoxy-13-halo derivative which is finally selectively reduced, for example using tributyltin hydride. In order to avoid unwanted side reactions it is desirable to protect any other hydroxy groups which may be present, for example using a tert-butyldimethylsilyl group. This is then readily removed after the halogenation or reduction step by treatment with methanol containing a trace of acid. All these steps together with appropriate reagents and reaction conditions for their performance are described in European patent application publication no.
0002615.
Compounds of the formula (I) wherein R is H, R is either H
or OH and the double bond is absent, may also be prepared by adding the appropriate carboxylic acid, or a salt, ester or amide 1339~80 thereof or oxidative precursor therefor, to a fermentation of a milbemycin producing organism, and isolating the desired milbemycin derivative having an unnaturai substituent group at the 25-position. Examples of milbemycin producing organisms include for instance Streptomyces hygroscopicus strain NRRL 5739 as described in ~ritish Patent Sepcification no. 1390336, Streptomyces cyaneogriseus subsp. noncyanogenus NRRL 15773 as described in European patent application publication no. 0170006 and Streptomyces thermoarchaenis NCIB 12015 as described in GB 2166436A.
The compounds of the invention are highly active antiparasitic agents having particular utility as anthelmintics, ectoparasiticides, insecticides and acaricides.
Thus the compounds are effective in treating a variety of conditions caused by endoparasites including, in particular, helminthiasis which is most frequently caused by a group of parasitic worms described as nematodes and which can cause severe economic losses in swine, sheep, horses and cattle as well as affecting domestic animals and poultry. The compounds are also effective against other nematodes which affect various species of animals including, for example, Dirofilaria in dogs and various parasites which can infect humans including gastro-intestinal parasites such as Ancylostoma, Necator, Ascaris, Strongyloides, Trichinella, Capillaria, Trichuris, Enterobius and parasites which are found in the blood or other tissues and organs such as filiarial worms and ~he extra intestinal stages of Strongyloides and Trichinella.
The compounds are also of value in treating ectoparasite infections including in particular arthropod ectoparasites of ~nimals and birds such as ticks, mites, lice, fleas, blowfly, biting insects and migrating dipterous larvae which can affect cattle and horses.
The compounds are also insecticides active against household pests such as the cockroach, clothes moth, carpet beetle and the housefly as well as being useful against insect pests of stored grain and of agricultural plants such as spider mites, aphids, caterpillars and against migratory orthopterans such as locusts.
The compounds of formula (I) are administered as a formulation appropriate to the speciflc use envisaged and to the particular species of host animal being treated and the parasite or insect involved. For use as an anthelmintic the compounds may be administered orally in the form of a capsule, bolus, tablet or preferably a liquid drench, or alternatively, they may be admin-istered by injection or as an implant. Such formulations are prepared in a conventional manner in accordance with standard veterinary practice. Thus capsules, boluses or tablets may be prepared by mixing the active ingredient with a suitable finely divided diluent or carrier additionally containing a disintigrat-ing agent and/or binder such as starch, lactose, talc, magnesium stearate etc. A drench formulation may be prepared by dispersing the active ingredient in an aqueous solution together with dispersing or wetting agents etc. and injectable formulations may be prepared in the form of a sterile solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. These formulations will vary with regard to the weight of active compound depending on the species of host animal to be treated, the severity and type of infection and the body weight of the host. Generally for oral administra-tion a dose of from about 0.001 to 10 mg per Kg of animal body weight given as a single dose or in divided doses for a period of from 1 to 5 days will be satisfactory but of course there can be instances where higher or lower dosage ranges are indicated and such are within the scope of this invention.
As an alternative the compounds may be administered with the animal feedstuff and for this purpose a concentrated feed additive or premix may be prepared for mixing with the normal animal feed.
For use as an insecticide and for treating agricultural pests the compounds are applied as sprays, dusts, emulsions and the like in accordance with standard agricultural practice.
The invention also extends to a commercial package containing a compound of the invention, together with instructions for its use in combating insect or parasite infections or infestations in humans or in animals or in agriculture or in horticulture.
The invention is illustrated by the following examples in which Examples 1 to 19 are examples of the preparation of compounds of the formula (I), Example 20 is an example of a drench formulation and Examples 21 and 22 illustrate the antiparasitic and insecticidal activity of the compounds.
25-Cyclopentyl-avermectin A2 A suspension of a slope culture of S. avermitilis NCI3 12121 was inoculated into 600 mls of a medium cont~ining lactose (12.0g), distillers solu~les (8.0g) and yeast extract (3.0g), contained in a 3 litre flask, and incubated at 28 C for 3 days.
The inoculum was used to inoculate 16 litres of a medium containing soluble starch (640g), ammonium sulphate (32g), dipotassium hydrogen phosphate (16g), sodium chloride (16g), magnesium sulphate 7H2O (16g), calcium carbonate (32g), soluble yeast extract (6.4g), ferrous sulphate 7H2O (0.016g), zinc sulphate 7H2O (0.016g) and manganese chloride 4H2O (0.016g), contained in a 20 litre fermenter. The fermentation was incubated at 28~C, with agitation at 250 r.p.m. and aerated at 15 litres per minute. Cyclopentane carboxylic acid sodium salt (1.6g) was added after 24 hours and again after 48 and 72 hours incubation and the fermentation was continued for 120 hours. After this time the mycelium was removed by filtration and extracted with acetone:
lN-hydrochloric acid (100:1; 3 x 7 litres). The extract was concentrated to approximately 2 litres under reduced pressure and extracted with methylene chloride (2 x 5 litres). The methylene chloride extract was concentrated to dryness to give the crude product as a mobile oil which was dissolved in diethyl ether and added to a column of silica gel (1 kg). The column was eluted with diethyl ether collecting 100 ml fractions. Fractions 20-40 were combined and the solvent evaporated to yield partially purified material. The product was dissolved in a mixture of methanol and water (4:1) and chromatographed on a Cl8 Micro-Bondapack column (50 mm x 50 cm) in a Waters Prep 500 high pressure liquid chromatograph using the same solvent at a flow rate of 100 ml per minute. Fractions 35 to 50 cont~ining the desired product were combined and rechromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x 25 cm) eluting with a mixture of methanol and water (4:1) at a flow rate of 9 mls. per minute. The relevant fractions were combined and the solvent evaporated to yield the compound of formula (I) wherein R is OH, 1339~80 the double bond is absent, R is cyclopentyl, R is CH3 and R is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy as a white powder.
m.p. 15~.5-151~C. The structure ol the product was confirmed by mass spectrometry and by C13 nuclear magnetic resonance spectroscopy as follows:
Fast atom bombardment mass spectrometry was performed on a VG
Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 9~9 (theoretical 939).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments were: 335, 317, 275, 257, 251, 233, 205, 181, 179, 145, 127, 113, 111, 95 and 87.
The 13C nuclear magnetic resonance spectral data were obtained on a Brucker Model WM-250 spectrometer with a sample concentration of 20 mg/ml in deuterochloroform. The chemical shifts in parts per million relative to tetramethylsilane were:
14.1, 15.3, 17.8, 18.5, 19.9, 20.3, 24.6, 25.9, 26.2, 29.3, 34.4 (2C), 34.7, 36.7, 37.8, 39.8, 40.~, 41.0, 41.3, 45.8, 56.4, 56.6, 57.8, 67.4; 67.6, 68.0, 68.3, 68.7, 69.9, 70.5, 76.0, 77.6 (2C), 78.3, 79.5, 80.7 (2C), 81.8, 94.9, 98.7, 99.8, 117.7, 118.5, 113.8, 125.0, 135.8, 136.3, 137.8, 140.1 and 173.8.
A suspension of a slope culture of S. avermitilis ATCC 3i271 was inoculated into 50 mls of a medium containing lactose (l.Og), distillers solubles (0.75g) and yeast extract (0.25g), contained in a 350 ml flask, and incubated at 28~C for 3 days. This inoculum (4 mls) was used to inoculate each of 50 flasks containing 50 mls of medium cont~ining corn starch (2.0g), soya flour (0.35g) and yeast extract (0.25g) contained in a 350 ml flask, and the flasks were incubated at 28~C.
After 24 hours, cyclopentane carboxylic acid sodium salt (5 mg) was added to each flask and incubation was continued for a further 5 days. After this time the contents of the flasks were bulked and the mycelium separated by centrifugation. The mycelium was extracted with acetone:lN-hydrochloric acid (100:1) and the acetone extract concentrated to dryness. The extract was analysed by high pressure liquid chromatography and was shown to contain a product identical with the product of Example 1.
An inoculum was prepared as described in Example 1 and used to inoculate 50 mls of the medium as used in Example 1, contained in 350 ml flasks. After incubation for 24 hours, 2-amino-cyclopentyl acetic acid (cyclopentylglycine) (5 mg) was added and the fermentation was continued for a further 5 days. The product was recovered by extraction of the mycelium with acetone and methylene chloride. The extract was analysed by HPLC which indicated that the product contained a compound identical to the product of Example 1.
~, The conditions of Example 3 were followed except that cyclopentyl methanol was used as substrate with similar results.
The conditions of Example 3 were followed except that the methyl ester of cyclopentane carboxylic acid, dissolved in methanol, was used as substrate with similar results.
The conditions of Example 3 were followed except that cyclopentane carboxylic acid, dissolved in methanol was used as substrate with similar results.
E~YAMPLE 7 25-(Thien-3-yl)avermectin A suspension of a slope culture of S. avermitilis NCIB 12121 was inoculated into 600 mls of a medium cont~ining lactose (12.0g), distillers solubles (8.0g) and yeast extract (3.Cg), contained in a 3 litre flask, and incubated at 28 C for 3 days.
The inoculum was used to inoculate 16 litres of a medium containing soluble starch (640g), ammonium sulphate (32g), 1339~80 dipotassium hydrogen phosphate tl6g), sodium chloride (16g), magnesium sulphate 7H20 (16g), calcium carbonate (32g), soluble yeast extract ~6.4g), ferrous sulphate 7H20 (0.016g), zinc sulphate 7H20 (0.016g) and manganese chloride 4H20 (0.016g), contained in a 20 litre fermenter. The fermentation was incubated at 28 C, with agitation at 250 r.p.m. ana aerated at 15 litres per minute. Thiophene-3-carboxylic acid sodium salt (1.6g) was added after 24 hours and again after 48 and 72 hours incubation and the fermentation was continued for 120 hours. After this time the mycelium was removed by filtration and extracted with acetone:
lN-hydrochloric acid (100:1; 3 x 7 litres). The extract was concentrated to approximately 2 litres under reduced pressure and extracted with methylene chloride (2 x 5 litres). The methylene chloride extract was concentrated to dryness to give the crude product as a mobile oil which was dissolved in diethyl ether and added to a column of silica gel (1 kg). The column was eluted with diethyl ether collecting 200 ml fractions. Fractions 32-45 were combined and the solvent evaporated to yield partially purified material. The product was dissolved in a mixture of methanol and water (3:1) and chromatographed on a C18 Micro-Bondapack column (50 mm x 50 cm) in a Waters Prep 500 high pressure liquid chromatograph using the same solvent at a flow rate of 100 ml per minute. Fractions 27 to 36 cont~ining the desired product were combined and rechromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x 25 cm) eluting with a mixture of methanol and water (3:1) at a flow rate of 9 mls. per minute. The relevant fractions were combined and the solvent evaporated to yield the compound of formula (I) wherein Rl is OH, the double bond is absent, R is thien-3-yl, R is CH3 and R is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy as a white powder.
m.p. 167~C. The structure of the product was confirmed by mass spectrometry as follows:
Fast atom bombardment mass spectrometry was performed on a VG
Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 953 (theoretical 953).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the prir.cipal fragments were: 349, 331, 275, 265, 257, 247, 237, 219, l9S, 145, 127, 113, 95 and 87.
A vegetative cell suspension of S. avermitilis NCIB 12121, held at -60~C in 10% v/v aqueous (2 mls) glycerol was inoculated into 50 ml of medium containing lactose (1.0 g), distillers solubles (0.75 g) amd yeast extract tO.25 g) contained in a 300 ml conical flask and incubated at 28~C for 24 hours, with shaking.
The inoculum was then added to 600 ml of the above medium contained in a 3 litre flask and the mixture was incubated at 28~C
for 24 hours with shaking. The product was used to inoculate 10 litres of the above medium contained in a 16 litre fermenter which was incubated at 28~C for 24 hours at an agitation speed of 350 r.p.m. with aeration at 10 litres of air per minute. This fermentation (600 ml) was used to inoculate 16 litres of a medium cont~;n;ng partially hydrolysed starch (640 g) ammonium sulphate (32 g), dipotassium hydrogen phosphate (16g), sodium chloride (16 g) magnesium sulphate 7H20 (16 g), calcium carbonate (32 g), soluble yeast extract (6.4 g), ferrous sulphate 7H20 (0.016g), zinc sulphate 7H20 (0.016 g), and manganese chloride 4H20 (0.016 g), contained in a 20 litre fermenter. The fermentation was incubated at 28~C, with agitation at 350 r.p.m. and aerated at 15 litres per minute. Cyclobutane carboxylic acid sodium salt (1.
g) was added after 24 hours and again after 48 and 72 hours incubation and the fermentation was continued for 120 hours.
After this time the mycelium was removed by filtration and extracted with acetone (3 x 7 litres). The extract was concentrated to approximately 2 litres under reduced pressure and extracted with methylene chloride (2 x 5 litres). The methylene chloride was concentrated to dryness to give the srude product as a mobile oil. This was taken up in iso-octane (150 ml~ and the solution extracted with a mixture of methanol (95 ml) and water (5 ml). Evaporation of the methanolic extract gave partially purified material which was separated into its individual components by high pressure liquid chromatography as follows:
The residue was dissolved in a little methanol and 1~39480 chromatographed in a C18 Micro-Bondapack column (50 mm x 50 cm) in a Waters Prep 500 high pressure liquid chromatograph using a mixture of methanol/water (4:1) at a flow rate of 100 ml per minute. Fractions 1 to 4 were combined and used in Example 9, fractions 5 to 9 were combined and used in Example 10, fractions 10 to 19 were combined and used in Example 11 and fractions 20 to 35 were combined and used in Example 12.
25-Cyclobutyl-avermectin B2 (R = OH, R3 = H) The combined fractions 1 to 4 from Example 8 were evaporated to dryness and the residue was re-chromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x Z5 cm) eluting with a mixture of methanol and water (3:1) at a flow rate of 9mls per minute. The relevant fractions were combined, the solvent evaporated and the product subjected to a final purification on a Silica Spherisorb 5 micron (Trademark, HPLC Technology) column (10.5 mm x 25 cm) eluting with a mixture of methylene chloride and methanol (98:2) at a flow rate of 4 mls per minute. The relevant fractions were combined and the solvent evaporated to yield the compound of formula (I) wherein R is OH, the double bond is absent, R is cyclobutyl, R3 is H and R is 4'-(alp~a-L-oleandrosyl)-L-oleandrosyloxy, as a white powder. m.p.
110-112~C. The structure of the product was confirmed by mass spectrometry as follows:-Fast atom bombardment mass spectrometry was performed on a VGModel 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 911 (theoretical 911).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments were: 321, 303, 261, 257, 237, 219, 209, 191, 179, 167, 145, 127, 113, 111, 95 and 87.
E.YAMPLE 10 25-Cyclobutyl-avermectin A2 (R = OH, R ~ CH3) The combined fractions 5 to 9 from Example 8 were evaporated to dryness and the residue was rechromatographed twice on a C18 Zorbax ODS (Trademark, Dupont) column, (21 mm x 25 cm) eluting with a methanol and water mixture (77:23) at a flow rate of 9 mls per minute. Suitable fractions were combined and evaporated to yield the compound of formula (I) wh~rein Rl is OH, the double bond is absent, R is cyclobutyl, R is CH3 and R is 4'-(alpha-L-oleandrosyl)-L-oleandrosyloxy as a white powder m.p.
135-140~C.
The structure of the product was confirmed by mass spectrometry as follows:
Fast atom bombardment mass spectrometry was performed on a VG
Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 925 (theoretical 925).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments were: 596, 454, 321, 303, 275, 237, 219, 209, 191, 179, 167, 145, 127, 113, 111, 95 and 87.
25-Cyclobutyl-avermectin Bl (22,23-Double bond present, R = H) The combined fractions 10 to 19 from Example 8 were evaporated to dryness and the residue dissolved in methanol and chromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x 25 cm) eluting with a mixture of methanol and water (4:1) at a flow rate of 9 mls per minute. The relevant fractions were combined and the solvent evaporated to give a product which was re-chromatographed on a Silica Zorbax SIL (Trademark, Dupont) column (21 mm x 25 cm) eluting with a mixture of dichloromethane and methanol (98.5:1.5) at a flow rate of 9 mls per minute. The .elevant fractions were combined and the solvent evaporated to yield the compound of formula (I) wherein Rl is absent, ~he double bond is present, R is cyclobutyl, R is H and R is 4'-(alpha-L-oleandrosyl)-L- oleandrosyloxy, as a white powder m.2.
135-138~C. The structure of the product was confirmed by mass spectrometry as fo ;ows:-Fast atom bombardment mass spectrometry was performed on a VGModel 7070E mass spectrometer using a sample matrix of triethylene glycol with soiid sodium chloride. (M + Na) observed ad m/e 893 (theoretical 893).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments ~ere: 303, 261, 257, 219, 191, 167, 145, i27, 113, 111, 95 and 87.
25-Cyclobutyl-avermectin Al (22,23-Double bond present, R = CH3) The combined fractions 20 to 35 from Example 8 were evaporated to dryness and the residue chromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x 25 cm) at a flow rate of 9 mls per minute. The relevant fractions were combined, the solvent evaporated and the product was rechromatographed on a Silica Sperisorb 5 micron (Trademark, HPLC Technology) column (10.5 mm x 25 cm) eluting with a mixture of dichloromethane and methanol (98.5 : 1.5) at a flow rate of 4 mls per minute.
Combination of the relevant fractions followed by evaporation gave the compound of formula (I) wherein R is absent, the double bond is present, R is cyclobutyl, R is CH3 and R is 4'-(alpha-L-oleandrosyl)-L- oleandrosyloxy as a white powder m.p.
120-124~C. The structure of the product was confirmed by mass spectrometry as follows:-Fast atom bombardment mass spectrometry was performed on a VGModel 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 907 (theoretical 907).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments were: 578, 303, 275, 257, 219, 191, 167, 145, 127, 113, 111, 95 and 87.
25-(Cyclohex-3-enyl)avermectin A2 The medium and conditions of Example 1 were followed except that 3-cyclohexenoic acid sodium salt was used as the substrate eO
yield the compound of formula I wherein Rl is OH, the double bond is absent, R is cyclohex-3-enyl, R is CH3 and R is 4'-(alpha-L-oleandrosyl)-alpha-L- oleandrosyloxy as a white powder mpt. 131-5~C.
~3~80 The structure of the product was confirmed by mass spectrometry as follows:
Fast atcm bombardment mass spectro~etry was performed on a VG
Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 951 (theoretical 951).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments were: 624, 480, 347, 329, 275, 263, 245, 235, 217, 205, 193, 179, 145, 127, 113, 111, 95 and 87.
25-Cyclohexyl avermectin A2 The medium and conditions of Example 1 were followed except that cyclohexane carboxylic acid sodium salt was used as the substrate to yield the compound of formula I whereln R is OH, R
is cyclohexyl, R is CH3 and R is 4'-(alpha-oleandroxyl)-alpha-L-oleandrosyloxy as a white powder mpt. 112-117~C.
The structure of the product was confirmed by mass spectrometry as follows:
Fast atom bombardment mass spectrometry was performed on a VG
Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 953 (theoretical 953).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments were: 624, 482, 349, 331, 275, 265, 247, 237, 219, 207, l9S, 179, 145, 127, 113, 111, 95 and 87.
25-(1-Methylthioethyl)avermectin A2 The medium aDd conditions of Example 1 were followed except that 2-methylthiopropionic acid sodium salt was used as the substrate to yield the compound of formula I wherein Rl is OH, R
is l-methylthioethyl, R3 is CH3 and R is 4'-(alpha-L-oleandroxyl)-oleandroxyloxy as a white powder, m.p. 134-138~C.
The structure of the product was confirmed by mass spectrometry as follows:
Fast atom bombardment ~ass spectrometry was performed on a VG
Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 945 (theoretical 945).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments were: 341, 323, 275, 263, 257, 239, 211, 187, 179, 145, 127, ~13, 111, 95 and 87.
., 25-(2-Methylcyclopropyl)avermectin A2 The medium and conditions of Example 1 were followed except that 2-methylcyclopropane carboxylic acid sodium salt was used as the substrate to yield the compound of formula I wherein Rl is OH, R is 2-methylcyclopropyl, R is CH3 and R4 is 4'-(alpha-L-oleandrosyl)-oleandroxyloxy, as a white powder, m.p. 147-150~C.
The structure of the product was confirmed by mass spectrometry as follows:
Fast atom bombardment mass spectrometry was performed on a VG
Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 925 (theoretical 925).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments were: 596, 454, 303, 275, 237, 219, 209, 191, 179, 167, 145, 127, 113, 111, 95 and 87.
The procedure of Example 1 was followed but using the sodium salt of the following carboxylic acids as substrate instead of cyclopentane carboxylic acid to yield the appropriate 25-substituted avermectins of formula (I) wherein Rl is OH and the double bond is absent or wherein the double bond is present and R
is absent, R is H or OH and R is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy:
2-methylvaleric ac.d 2,3-dimethylbutyric acid 2-methylhexanoic acid 2-methylpent-4-enoic acid 2-methylpentanoic acid 2-cyclopropyl propionic acid cycloheptane carboxylic acid 4,4-difluorocyclohexane carboxylic acid 4-methylenecyclohexane carboxylic acid 3-methylcyclohexane carboxylic acid cyclopentene-l-carboxylic acid l-cyclohexene carboxylic acid tetrahydropyran-4-carboxylic acid thiophene-2-carboxylic acid 3-furoic acid and 2-chloro-thiophene-4-carboxylic acid.
25-Cyclobutyl-22,23-dihydro-avermectin Bl The product of Example 11 in benzene is hydrogenated in the presence of tris(triphenylphosphine)rhodium (I) chloride according to the procedure of EP-A-0001689 to yield the corresponding compound of formula (I) wherein R is H and the double bond is absent.
13-Deoxy-25-cyclopentyl-avermectin A2-aglycone The product of Example 1 is treated with dilute sulphuric acid at room temperature and the resulting aglycone product is isolated and reacted with t-butyldimethylsilylchloride in dimethylformamide to provide the 23-0-t-butyldimethylsilyl aglycone derivative. This is dissolved in methylene chloride containing 4-dimethylaminopyridine and diisopropylethylamine, cooled in ice and treated dropwise with 4-nitrobenzene-21sulphonylchloride to yield the 13-chloro-13-deoxy product. This is finally dehalogenated by reaction with tributyltinhydride and depro~ected with methanol cont~in;ng a trace of para-toluene sulphonic acid following the procedures described in EP-A-0002515 to provide che compound of the formula I wherein R and R are each H, R is OH, the double bond is absent and R is cyclopentyl.
Drench Formulation The product of any one of the preceding Examples was dissolved in polyethylene glycol (average molecular weight 300) to give a solution containing 400 micrograms/ml for use as a drench formulation.
Anthelmintic Activity Anthelmintic activity was evaluated against Caenorhabditis elegans using the in vitro screening test described by K. G.
Simpkin and G. L. Coles in Parisitology, 1979, 79, 19. The products of E~amples l, 7 and 9-16 all killed 100% of the worms at a well concentration of 0.1 micrograms per ml.
Insecticidal Activity Activity against adult house fly Musca domestica is demonstrated using a standard test procedure in which the flies are anaesthetised under carbon dioxide and 0.1 microlitres of acetone containing the test compound is deposited on the thorax of female flies. The product of Examples l, 7 and 9-15 all killed 100% of the treated flies at a dose of O.Ol micrograms per fly.
In another preferred aspect of the invention, the fermentation is performed in the presence of thiophene-3-carboxylic acid sodium salt to yield predominantly the compound of formula (I) wherein Rl is OH, the double bond i3 absent, R is thien-3-yl, R is CH3 and R is 4'-(alpha-L-oleandrosyl)-alpha-4-oleandrosyloxy.
In a further preferred aspect of the invention the fermentation is performed in the presence of 2-methylthiopropionic acid sodium salt to yield predominantly the compound of formula (I) wherein R is OH, the double bond is absent, R is l-methylthioethyl, R3 is CH and R is 4'-(alpha-L-oleandrosyl)-alpha-4-oleandrosyloxy.
Compounds of the formula (I) wherein the double bond is present and R is absent may alternatively be prepared from the corresponding compound of formula (I) wherein R is OH and the double bond is absent by a dehydration reaction. The reaction is performed by first selectively protecting the hydroxyl groups at the 5 and 4" posi-tions, e.g. as the t-butyldimethylsilyloxy acetyl derivative, then reacting with a substituted thiocarbonyl halide, such as (4-methylphenoxy)thiocarbonyl chloride, followed by heating in a high boiling point solvent, e.g. trichlorobenzene, to effect the dehydration. The product is finally deprotected to give the unsaturated compound. These steps together with appropriate reagents and reaction conditions are described in United States patent 4328335.
The compounds of formula I wherein R3 is H may also be prepared from the corresponding compounds wherein R is CH3 by demethylat~on. This reaction is achieved by treating the 5-methoxy compound, or a suitably protected derivative thereof, with mercuric acetate and hydrolysing the resulting 3-acetoxy enol ether with dilute acid to give the 5-keto compound. This is then reduced using, for example, sodium borohydride to yield the 5-hydroxy derivative. Appropriate reagents and reaction conditions for these steps are described in United States patent 4423209.
The compounds of formula I wherein R is H and the double bond is absent can be prepared from the corresponding compound wherein the double bond is present and Rl is absent, by selective catalytic hydrogenation using an appropriate catalyst. For example the reduction may be achieved using tris(triphenyl-phosphine)rhodium (I) chloride as described in European patent application publication no. 0001689.
The compounds of formula (I) wherein R is H are prepared from the corresponding compounds wherein R is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy by removing the 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrose group by mild hydrolysis with an acid in an aqueous organic solvent to yield the aglycone having a hydroxy group at the 13-position; this is then halogenated, for example by reaction with a benzene sulphonyl halide, to yield the 13-deoxy-13-halo derivative which is finally selectively reduced, for example using tributyltin hydride. In order to avoid unwanted side reactions it is desirable to protect any other hydroxy groups which may be present, for example using a tert-butyldimethylsilyl group. This is then readily removed after the halogenation or reduction step by treatment with methanol containing a trace of acid. All these steps together with appropriate reagents and reaction conditions for their performance are described in European patent application publication no.
0002615.
Compounds of the formula (I) wherein R is H, R is either H
or OH and the double bond is absent, may also be prepared by adding the appropriate carboxylic acid, or a salt, ester or amide 1339~80 thereof or oxidative precursor therefor, to a fermentation of a milbemycin producing organism, and isolating the desired milbemycin derivative having an unnaturai substituent group at the 25-position. Examples of milbemycin producing organisms include for instance Streptomyces hygroscopicus strain NRRL 5739 as described in ~ritish Patent Sepcification no. 1390336, Streptomyces cyaneogriseus subsp. noncyanogenus NRRL 15773 as described in European patent application publication no. 0170006 and Streptomyces thermoarchaenis NCIB 12015 as described in GB 2166436A.
The compounds of the invention are highly active antiparasitic agents having particular utility as anthelmintics, ectoparasiticides, insecticides and acaricides.
Thus the compounds are effective in treating a variety of conditions caused by endoparasites including, in particular, helminthiasis which is most frequently caused by a group of parasitic worms described as nematodes and which can cause severe economic losses in swine, sheep, horses and cattle as well as affecting domestic animals and poultry. The compounds are also effective against other nematodes which affect various species of animals including, for example, Dirofilaria in dogs and various parasites which can infect humans including gastro-intestinal parasites such as Ancylostoma, Necator, Ascaris, Strongyloides, Trichinella, Capillaria, Trichuris, Enterobius and parasites which are found in the blood or other tissues and organs such as filiarial worms and ~he extra intestinal stages of Strongyloides and Trichinella.
The compounds are also of value in treating ectoparasite infections including in particular arthropod ectoparasites of ~nimals and birds such as ticks, mites, lice, fleas, blowfly, biting insects and migrating dipterous larvae which can affect cattle and horses.
The compounds are also insecticides active against household pests such as the cockroach, clothes moth, carpet beetle and the housefly as well as being useful against insect pests of stored grain and of agricultural plants such as spider mites, aphids, caterpillars and against migratory orthopterans such as locusts.
The compounds of formula (I) are administered as a formulation appropriate to the speciflc use envisaged and to the particular species of host animal being treated and the parasite or insect involved. For use as an anthelmintic the compounds may be administered orally in the form of a capsule, bolus, tablet or preferably a liquid drench, or alternatively, they may be admin-istered by injection or as an implant. Such formulations are prepared in a conventional manner in accordance with standard veterinary practice. Thus capsules, boluses or tablets may be prepared by mixing the active ingredient with a suitable finely divided diluent or carrier additionally containing a disintigrat-ing agent and/or binder such as starch, lactose, talc, magnesium stearate etc. A drench formulation may be prepared by dispersing the active ingredient in an aqueous solution together with dispersing or wetting agents etc. and injectable formulations may be prepared in the form of a sterile solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. These formulations will vary with regard to the weight of active compound depending on the species of host animal to be treated, the severity and type of infection and the body weight of the host. Generally for oral administra-tion a dose of from about 0.001 to 10 mg per Kg of animal body weight given as a single dose or in divided doses for a period of from 1 to 5 days will be satisfactory but of course there can be instances where higher or lower dosage ranges are indicated and such are within the scope of this invention.
As an alternative the compounds may be administered with the animal feedstuff and for this purpose a concentrated feed additive or premix may be prepared for mixing with the normal animal feed.
For use as an insecticide and for treating agricultural pests the compounds are applied as sprays, dusts, emulsions and the like in accordance with standard agricultural practice.
The invention also extends to a commercial package containing a compound of the invention, together with instructions for its use in combating insect or parasite infections or infestations in humans or in animals or in agriculture or in horticulture.
The invention is illustrated by the following examples in which Examples 1 to 19 are examples of the preparation of compounds of the formula (I), Example 20 is an example of a drench formulation and Examples 21 and 22 illustrate the antiparasitic and insecticidal activity of the compounds.
25-Cyclopentyl-avermectin A2 A suspension of a slope culture of S. avermitilis NCI3 12121 was inoculated into 600 mls of a medium cont~ining lactose (12.0g), distillers solu~les (8.0g) and yeast extract (3.0g), contained in a 3 litre flask, and incubated at 28 C for 3 days.
The inoculum was used to inoculate 16 litres of a medium containing soluble starch (640g), ammonium sulphate (32g), dipotassium hydrogen phosphate (16g), sodium chloride (16g), magnesium sulphate 7H2O (16g), calcium carbonate (32g), soluble yeast extract (6.4g), ferrous sulphate 7H2O (0.016g), zinc sulphate 7H2O (0.016g) and manganese chloride 4H2O (0.016g), contained in a 20 litre fermenter. The fermentation was incubated at 28~C, with agitation at 250 r.p.m. and aerated at 15 litres per minute. Cyclopentane carboxylic acid sodium salt (1.6g) was added after 24 hours and again after 48 and 72 hours incubation and the fermentation was continued for 120 hours. After this time the mycelium was removed by filtration and extracted with acetone:
lN-hydrochloric acid (100:1; 3 x 7 litres). The extract was concentrated to approximately 2 litres under reduced pressure and extracted with methylene chloride (2 x 5 litres). The methylene chloride extract was concentrated to dryness to give the crude product as a mobile oil which was dissolved in diethyl ether and added to a column of silica gel (1 kg). The column was eluted with diethyl ether collecting 100 ml fractions. Fractions 20-40 were combined and the solvent evaporated to yield partially purified material. The product was dissolved in a mixture of methanol and water (4:1) and chromatographed on a Cl8 Micro-Bondapack column (50 mm x 50 cm) in a Waters Prep 500 high pressure liquid chromatograph using the same solvent at a flow rate of 100 ml per minute. Fractions 35 to 50 cont~ining the desired product were combined and rechromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x 25 cm) eluting with a mixture of methanol and water (4:1) at a flow rate of 9 mls. per minute. The relevant fractions were combined and the solvent evaporated to yield the compound of formula (I) wherein R is OH, 1339~80 the double bond is absent, R is cyclopentyl, R is CH3 and R is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy as a white powder.
m.p. 15~.5-151~C. The structure ol the product was confirmed by mass spectrometry and by C13 nuclear magnetic resonance spectroscopy as follows:
Fast atom bombardment mass spectrometry was performed on a VG
Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 9~9 (theoretical 939).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments were: 335, 317, 275, 257, 251, 233, 205, 181, 179, 145, 127, 113, 111, 95 and 87.
The 13C nuclear magnetic resonance spectral data were obtained on a Brucker Model WM-250 spectrometer with a sample concentration of 20 mg/ml in deuterochloroform. The chemical shifts in parts per million relative to tetramethylsilane were:
14.1, 15.3, 17.8, 18.5, 19.9, 20.3, 24.6, 25.9, 26.2, 29.3, 34.4 (2C), 34.7, 36.7, 37.8, 39.8, 40.~, 41.0, 41.3, 45.8, 56.4, 56.6, 57.8, 67.4; 67.6, 68.0, 68.3, 68.7, 69.9, 70.5, 76.0, 77.6 (2C), 78.3, 79.5, 80.7 (2C), 81.8, 94.9, 98.7, 99.8, 117.7, 118.5, 113.8, 125.0, 135.8, 136.3, 137.8, 140.1 and 173.8.
A suspension of a slope culture of S. avermitilis ATCC 3i271 was inoculated into 50 mls of a medium containing lactose (l.Og), distillers solubles (0.75g) and yeast extract (0.25g), contained in a 350 ml flask, and incubated at 28~C for 3 days. This inoculum (4 mls) was used to inoculate each of 50 flasks containing 50 mls of medium cont~ining corn starch (2.0g), soya flour (0.35g) and yeast extract (0.25g) contained in a 350 ml flask, and the flasks were incubated at 28~C.
After 24 hours, cyclopentane carboxylic acid sodium salt (5 mg) was added to each flask and incubation was continued for a further 5 days. After this time the contents of the flasks were bulked and the mycelium separated by centrifugation. The mycelium was extracted with acetone:lN-hydrochloric acid (100:1) and the acetone extract concentrated to dryness. The extract was analysed by high pressure liquid chromatography and was shown to contain a product identical with the product of Example 1.
An inoculum was prepared as described in Example 1 and used to inoculate 50 mls of the medium as used in Example 1, contained in 350 ml flasks. After incubation for 24 hours, 2-amino-cyclopentyl acetic acid (cyclopentylglycine) (5 mg) was added and the fermentation was continued for a further 5 days. The product was recovered by extraction of the mycelium with acetone and methylene chloride. The extract was analysed by HPLC which indicated that the product contained a compound identical to the product of Example 1.
~, The conditions of Example 3 were followed except that cyclopentyl methanol was used as substrate with similar results.
The conditions of Example 3 were followed except that the methyl ester of cyclopentane carboxylic acid, dissolved in methanol, was used as substrate with similar results.
The conditions of Example 3 were followed except that cyclopentane carboxylic acid, dissolved in methanol was used as substrate with similar results.
E~YAMPLE 7 25-(Thien-3-yl)avermectin A suspension of a slope culture of S. avermitilis NCIB 12121 was inoculated into 600 mls of a medium cont~ining lactose (12.0g), distillers solubles (8.0g) and yeast extract (3.Cg), contained in a 3 litre flask, and incubated at 28 C for 3 days.
The inoculum was used to inoculate 16 litres of a medium containing soluble starch (640g), ammonium sulphate (32g), 1339~80 dipotassium hydrogen phosphate tl6g), sodium chloride (16g), magnesium sulphate 7H20 (16g), calcium carbonate (32g), soluble yeast extract ~6.4g), ferrous sulphate 7H20 (0.016g), zinc sulphate 7H20 (0.016g) and manganese chloride 4H20 (0.016g), contained in a 20 litre fermenter. The fermentation was incubated at 28 C, with agitation at 250 r.p.m. ana aerated at 15 litres per minute. Thiophene-3-carboxylic acid sodium salt (1.6g) was added after 24 hours and again after 48 and 72 hours incubation and the fermentation was continued for 120 hours. After this time the mycelium was removed by filtration and extracted with acetone:
lN-hydrochloric acid (100:1; 3 x 7 litres). The extract was concentrated to approximately 2 litres under reduced pressure and extracted with methylene chloride (2 x 5 litres). The methylene chloride extract was concentrated to dryness to give the crude product as a mobile oil which was dissolved in diethyl ether and added to a column of silica gel (1 kg). The column was eluted with diethyl ether collecting 200 ml fractions. Fractions 32-45 were combined and the solvent evaporated to yield partially purified material. The product was dissolved in a mixture of methanol and water (3:1) and chromatographed on a C18 Micro-Bondapack column (50 mm x 50 cm) in a Waters Prep 500 high pressure liquid chromatograph using the same solvent at a flow rate of 100 ml per minute. Fractions 27 to 36 cont~ining the desired product were combined and rechromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x 25 cm) eluting with a mixture of methanol and water (3:1) at a flow rate of 9 mls. per minute. The relevant fractions were combined and the solvent evaporated to yield the compound of formula (I) wherein Rl is OH, the double bond is absent, R is thien-3-yl, R is CH3 and R is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy as a white powder.
m.p. 167~C. The structure of the product was confirmed by mass spectrometry as follows:
Fast atom bombardment mass spectrometry was performed on a VG
Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 953 (theoretical 953).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the prir.cipal fragments were: 349, 331, 275, 265, 257, 247, 237, 219, l9S, 145, 127, 113, 95 and 87.
A vegetative cell suspension of S. avermitilis NCIB 12121, held at -60~C in 10% v/v aqueous (2 mls) glycerol was inoculated into 50 ml of medium containing lactose (1.0 g), distillers solubles (0.75 g) amd yeast extract tO.25 g) contained in a 300 ml conical flask and incubated at 28~C for 24 hours, with shaking.
The inoculum was then added to 600 ml of the above medium contained in a 3 litre flask and the mixture was incubated at 28~C
for 24 hours with shaking. The product was used to inoculate 10 litres of the above medium contained in a 16 litre fermenter which was incubated at 28~C for 24 hours at an agitation speed of 350 r.p.m. with aeration at 10 litres of air per minute. This fermentation (600 ml) was used to inoculate 16 litres of a medium cont~;n;ng partially hydrolysed starch (640 g) ammonium sulphate (32 g), dipotassium hydrogen phosphate (16g), sodium chloride (16 g) magnesium sulphate 7H20 (16 g), calcium carbonate (32 g), soluble yeast extract (6.4 g), ferrous sulphate 7H20 (0.016g), zinc sulphate 7H20 (0.016 g), and manganese chloride 4H20 (0.016 g), contained in a 20 litre fermenter. The fermentation was incubated at 28~C, with agitation at 350 r.p.m. and aerated at 15 litres per minute. Cyclobutane carboxylic acid sodium salt (1.
g) was added after 24 hours and again after 48 and 72 hours incubation and the fermentation was continued for 120 hours.
After this time the mycelium was removed by filtration and extracted with acetone (3 x 7 litres). The extract was concentrated to approximately 2 litres under reduced pressure and extracted with methylene chloride (2 x 5 litres). The methylene chloride was concentrated to dryness to give the srude product as a mobile oil. This was taken up in iso-octane (150 ml~ and the solution extracted with a mixture of methanol (95 ml) and water (5 ml). Evaporation of the methanolic extract gave partially purified material which was separated into its individual components by high pressure liquid chromatography as follows:
The residue was dissolved in a little methanol and 1~39480 chromatographed in a C18 Micro-Bondapack column (50 mm x 50 cm) in a Waters Prep 500 high pressure liquid chromatograph using a mixture of methanol/water (4:1) at a flow rate of 100 ml per minute. Fractions 1 to 4 were combined and used in Example 9, fractions 5 to 9 were combined and used in Example 10, fractions 10 to 19 were combined and used in Example 11 and fractions 20 to 35 were combined and used in Example 12.
25-Cyclobutyl-avermectin B2 (R = OH, R3 = H) The combined fractions 1 to 4 from Example 8 were evaporated to dryness and the residue was re-chromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x Z5 cm) eluting with a mixture of methanol and water (3:1) at a flow rate of 9mls per minute. The relevant fractions were combined, the solvent evaporated and the product subjected to a final purification on a Silica Spherisorb 5 micron (Trademark, HPLC Technology) column (10.5 mm x 25 cm) eluting with a mixture of methylene chloride and methanol (98:2) at a flow rate of 4 mls per minute. The relevant fractions were combined and the solvent evaporated to yield the compound of formula (I) wherein R is OH, the double bond is absent, R is cyclobutyl, R3 is H and R is 4'-(alp~a-L-oleandrosyl)-L-oleandrosyloxy, as a white powder. m.p.
110-112~C. The structure of the product was confirmed by mass spectrometry as follows:-Fast atom bombardment mass spectrometry was performed on a VGModel 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 911 (theoretical 911).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments were: 321, 303, 261, 257, 237, 219, 209, 191, 179, 167, 145, 127, 113, 111, 95 and 87.
E.YAMPLE 10 25-Cyclobutyl-avermectin A2 (R = OH, R ~ CH3) The combined fractions 5 to 9 from Example 8 were evaporated to dryness and the residue was rechromatographed twice on a C18 Zorbax ODS (Trademark, Dupont) column, (21 mm x 25 cm) eluting with a methanol and water mixture (77:23) at a flow rate of 9 mls per minute. Suitable fractions were combined and evaporated to yield the compound of formula (I) wh~rein Rl is OH, the double bond is absent, R is cyclobutyl, R is CH3 and R is 4'-(alpha-L-oleandrosyl)-L-oleandrosyloxy as a white powder m.p.
135-140~C.
The structure of the product was confirmed by mass spectrometry as follows:
Fast atom bombardment mass spectrometry was performed on a VG
Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 925 (theoretical 925).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments were: 596, 454, 321, 303, 275, 237, 219, 209, 191, 179, 167, 145, 127, 113, 111, 95 and 87.
25-Cyclobutyl-avermectin Bl (22,23-Double bond present, R = H) The combined fractions 10 to 19 from Example 8 were evaporated to dryness and the residue dissolved in methanol and chromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x 25 cm) eluting with a mixture of methanol and water (4:1) at a flow rate of 9 mls per minute. The relevant fractions were combined and the solvent evaporated to give a product which was re-chromatographed on a Silica Zorbax SIL (Trademark, Dupont) column (21 mm x 25 cm) eluting with a mixture of dichloromethane and methanol (98.5:1.5) at a flow rate of 9 mls per minute. The .elevant fractions were combined and the solvent evaporated to yield the compound of formula (I) wherein Rl is absent, ~he double bond is present, R is cyclobutyl, R is H and R is 4'-(alpha-L-oleandrosyl)-L- oleandrosyloxy, as a white powder m.2.
135-138~C. The structure of the product was confirmed by mass spectrometry as fo ;ows:-Fast atom bombardment mass spectrometry was performed on a VGModel 7070E mass spectrometer using a sample matrix of triethylene glycol with soiid sodium chloride. (M + Na) observed ad m/e 893 (theoretical 893).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments ~ere: 303, 261, 257, 219, 191, 167, 145, i27, 113, 111, 95 and 87.
25-Cyclobutyl-avermectin Al (22,23-Double bond present, R = CH3) The combined fractions 20 to 35 from Example 8 were evaporated to dryness and the residue chromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x 25 cm) at a flow rate of 9 mls per minute. The relevant fractions were combined, the solvent evaporated and the product was rechromatographed on a Silica Sperisorb 5 micron (Trademark, HPLC Technology) column (10.5 mm x 25 cm) eluting with a mixture of dichloromethane and methanol (98.5 : 1.5) at a flow rate of 4 mls per minute.
Combination of the relevant fractions followed by evaporation gave the compound of formula (I) wherein R is absent, the double bond is present, R is cyclobutyl, R is CH3 and R is 4'-(alpha-L-oleandrosyl)-L- oleandrosyloxy as a white powder m.p.
120-124~C. The structure of the product was confirmed by mass spectrometry as follows:-Fast atom bombardment mass spectrometry was performed on a VGModel 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 907 (theoretical 907).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments were: 578, 303, 275, 257, 219, 191, 167, 145, 127, 113, 111, 95 and 87.
25-(Cyclohex-3-enyl)avermectin A2 The medium and conditions of Example 1 were followed except that 3-cyclohexenoic acid sodium salt was used as the substrate eO
yield the compound of formula I wherein Rl is OH, the double bond is absent, R is cyclohex-3-enyl, R is CH3 and R is 4'-(alpha-L-oleandrosyl)-alpha-L- oleandrosyloxy as a white powder mpt. 131-5~C.
~3~80 The structure of the product was confirmed by mass spectrometry as follows:
Fast atcm bombardment mass spectro~etry was performed on a VG
Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 951 (theoretical 951).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments were: 624, 480, 347, 329, 275, 263, 245, 235, 217, 205, 193, 179, 145, 127, 113, 111, 95 and 87.
25-Cyclohexyl avermectin A2 The medium and conditions of Example 1 were followed except that cyclohexane carboxylic acid sodium salt was used as the substrate to yield the compound of formula I whereln R is OH, R
is cyclohexyl, R is CH3 and R is 4'-(alpha-oleandroxyl)-alpha-L-oleandrosyloxy as a white powder mpt. 112-117~C.
The structure of the product was confirmed by mass spectrometry as follows:
Fast atom bombardment mass spectrometry was performed on a VG
Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 953 (theoretical 953).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments were: 624, 482, 349, 331, 275, 265, 247, 237, 219, 207, l9S, 179, 145, 127, 113, 111, 95 and 87.
25-(1-Methylthioethyl)avermectin A2 The medium aDd conditions of Example 1 were followed except that 2-methylthiopropionic acid sodium salt was used as the substrate to yield the compound of formula I wherein Rl is OH, R
is l-methylthioethyl, R3 is CH3 and R is 4'-(alpha-L-oleandroxyl)-oleandroxyloxy as a white powder, m.p. 134-138~C.
The structure of the product was confirmed by mass spectrometry as follows:
Fast atom bombardment ~ass spectrometry was performed on a VG
Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 945 (theoretical 945).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments were: 341, 323, 275, 263, 257, 239, 211, 187, 179, 145, 127, ~13, 111, 95 and 87.
., 25-(2-Methylcyclopropyl)avermectin A2 The medium and conditions of Example 1 were followed except that 2-methylcyclopropane carboxylic acid sodium salt was used as the substrate to yield the compound of formula I wherein Rl is OH, R is 2-methylcyclopropyl, R is CH3 and R4 is 4'-(alpha-L-oleandrosyl)-oleandroxyloxy, as a white powder, m.p. 147-150~C.
The structure of the product was confirmed by mass spectrometry as follows:
Fast atom bombardment mass spectrometry was performed on a VG
Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 925 (theoretical 925).
Electron impact mass spectrometry was performed using a VG
Model 7070F mass spectrometer. The m/e values for the principal fragments were: 596, 454, 303, 275, 237, 219, 209, 191, 179, 167, 145, 127, 113, 111, 95 and 87.
The procedure of Example 1 was followed but using the sodium salt of the following carboxylic acids as substrate instead of cyclopentane carboxylic acid to yield the appropriate 25-substituted avermectins of formula (I) wherein Rl is OH and the double bond is absent or wherein the double bond is present and R
is absent, R is H or OH and R is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy:
2-methylvaleric ac.d 2,3-dimethylbutyric acid 2-methylhexanoic acid 2-methylpent-4-enoic acid 2-methylpentanoic acid 2-cyclopropyl propionic acid cycloheptane carboxylic acid 4,4-difluorocyclohexane carboxylic acid 4-methylenecyclohexane carboxylic acid 3-methylcyclohexane carboxylic acid cyclopentene-l-carboxylic acid l-cyclohexene carboxylic acid tetrahydropyran-4-carboxylic acid thiophene-2-carboxylic acid 3-furoic acid and 2-chloro-thiophene-4-carboxylic acid.
25-Cyclobutyl-22,23-dihydro-avermectin Bl The product of Example 11 in benzene is hydrogenated in the presence of tris(triphenylphosphine)rhodium (I) chloride according to the procedure of EP-A-0001689 to yield the corresponding compound of formula (I) wherein R is H and the double bond is absent.
13-Deoxy-25-cyclopentyl-avermectin A2-aglycone The product of Example 1 is treated with dilute sulphuric acid at room temperature and the resulting aglycone product is isolated and reacted with t-butyldimethylsilylchloride in dimethylformamide to provide the 23-0-t-butyldimethylsilyl aglycone derivative. This is dissolved in methylene chloride containing 4-dimethylaminopyridine and diisopropylethylamine, cooled in ice and treated dropwise with 4-nitrobenzene-21sulphonylchloride to yield the 13-chloro-13-deoxy product. This is finally dehalogenated by reaction with tributyltinhydride and depro~ected with methanol cont~in;ng a trace of para-toluene sulphonic acid following the procedures described in EP-A-0002515 to provide che compound of the formula I wherein R and R are each H, R is OH, the double bond is absent and R is cyclopentyl.
Drench Formulation The product of any one of the preceding Examples was dissolved in polyethylene glycol (average molecular weight 300) to give a solution containing 400 micrograms/ml for use as a drench formulation.
Anthelmintic Activity Anthelmintic activity was evaluated against Caenorhabditis elegans using the in vitro screening test described by K. G.
Simpkin and G. L. Coles in Parisitology, 1979, 79, 19. The products of E~amples l, 7 and 9-16 all killed 100% of the worms at a well concentration of 0.1 micrograms per ml.
Insecticidal Activity Activity against adult house fly Musca domestica is demonstrated using a standard test procedure in which the flies are anaesthetised under carbon dioxide and 0.1 microlitres of acetone containing the test compound is deposited on the thorax of female flies. The product of Examples l, 7 and 9-15 all killed 100% of the treated flies at a dose of O.Ol micrograms per fly.
Claims (30)
1. A compound having the formula (I) wherein the broken line at the 22-23 position represents an optional double bond and wherein R1 is H or OH and the double bond is absent, or, the double bond is present and R1 is absent;
R2 is an alpha-branched C3-C8 alkyl group, an alpha-branched C3-C8 alkenyl group, an alpha-branched C3-C8 alkoxyalkyl group, an alpha-branched C3-C8 alkylthioalkyl group; a C5-C8 cycloalkylalkyl group wherein the alkyl group is an alpha-branched C2-C5 alkyl group; a C3-C8 cycloalkyl or C5-C8 cycloalkylkenyl group, either of which may optionally be substituted by methylene or one or more C1-C4 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C1-C4 alkyl groups or halo atoms;
R3 is hydrogen or methyl;
R4 is H or a 4'(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy group of the formula:
with the proviso that when R2 is alkyl it is not isopropyl or sec-butyl; and when R4 is H, R1 is OH, and the double bond is absent, R2 is not 2-buten-2-yl, 2-penten-2-yl or 4-methyl-2-penten-2-yl.
R2 is an alpha-branched C3-C8 alkyl group, an alpha-branched C3-C8 alkenyl group, an alpha-branched C3-C8 alkoxyalkyl group, an alpha-branched C3-C8 alkylthioalkyl group; a C5-C8 cycloalkylalkyl group wherein the alkyl group is an alpha-branched C2-C5 alkyl group; a C3-C8 cycloalkyl or C5-C8 cycloalkylkenyl group, either of which may optionally be substituted by methylene or one or more C1-C4 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C1-C4 alkyl groups or halo atoms;
R3 is hydrogen or methyl;
R4 is H or a 4'(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy group of the formula:
with the proviso that when R2 is alkyl it is not isopropyl or sec-butyl; and when R4 is H, R1 is OH, and the double bond is absent, R2 is not 2-buten-2-yl, 2-penten-2-yl or 4-methyl-2-penten-2-yl.
2. A compound of the formula I as claimed in claim 1 wherein R4 is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy.
3. A compound as claimed in claim 2 wherein R2 is a C5 or C6 cycloalkyl or cycloalkenyl group which may optionally be substituted by one or more C1-C4 alkyl groups.
4. A compound as claimed in claim 3 wherein R2 is an unsubstituted C5 or C6 cycloalkyl group.
5. A compound as claimed in claim 3 wherein R2 is cyclohexyl.
6. A compound as claimed in claim 3 wherein R2 is cyclopentyl.
7. A compound as claimed in claim 2 wherein R2 is cyclobutyl.
8. A compound as claimed in claim 2 wherein R2 is a 5 or 6 membered oxygen or sulphur containing heterocyclic ring which may optionally be substituted by chlorine.
9. A compound as claimed in claim 8 wherein R2 is 3-thienyl.
10. A compound as claimed in claim 2 wherein R2 is C3-C8 alkylthioalkyl group.
11. A compound as claimed in claim 10 wherein R2 is 1-methylthioethyl.
12. A compound as claimed in any one of claims 1 to 11 wherein R3 is H.
13. A compound as claimed in any one of claims 1 to 11 wherein R3 is a methyl group.
14. A compound as claimed in claim 12 wherein R1 is absent and the broken line at the 22,23 position represents a double bond.
15. A compound as claimed in claim 13 wherein R1 is absent and the broken line at the 22,23 position represents a double bond.
16. A compound as claimed in claim 12 wherein R1 is OH
and there is no double bond at the 22,23 position.
and there is no double bond at the 22,23 position.
17. A compound as claimed in claim 13 wherein R1 is OH
and there is no double bond at the 22,23 position.
and there is no double bond at the 22,23 position.
18. A compound as claimed in claim 12 wherein R1 is H
and there is no double bond at the 22,23 position.
and there is no double bond at the 22,23 position.
19. A compound as claimed in claim 13 wherein R1 is H
and there is no double bond at the 22,23 position.
and there is no double bond at the 22,23 position.
20. A C-25-cycloalkyl avermectin B1 in which the cycloalkyl group contains 5 or 6 carbon atoms.
21. C-25 cyclopentyl avermectin B1.
22. C-25 cyclohexyl avermectin B1.
23. A process for producing a compound of the formula (I) as claimed in claim 1 which comprises fermenting an avermectin producing strain of the organism Streptomyces avermitilis selected from the strains ATCC 31267, ATCC 31271, ATCC 31272 and NCIB 12121 in the presence of a carboxylic acid of the formula R2CO2H wherein R2 is as defined in claim 1, or a salt, ester or amide thereof or oxidative precursor therefor, and isolating the compound of formula (I) wherein R1 is OH and the double bond is absent or wherein the double bond is present and R1 is absent and R4 is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy and, if desired, reducing the compound wherein the double bond is present and R1 is absent to obtain the compound of formula (I) wherein R1 is H
and the double bond is absent or, if desired, removing the 4-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy group by hydrolysis followed by halogenation and reduction to yield the compound of formula (I) wherein R4 is H.
and the double bond is absent or, if desired, removing the 4-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy group by hydrolysis followed by halogenation and reduction to yield the compound of formula (I) wherein R4 is H.
24. A process as claimed in claim 23 wherein the organism is Streptomyces avermitilis NCIB 12121.
25. A composition for the treatment and prevention of parasitic infections in humans and animals, including ectoparasiticidal, insecticidal, acaricidal and anthelmintic compositions, which comprises a compound of the formula (I) as claimed in any one of claims 1 to 11 and 14 to 22 together with an inert diluent or carrier.
26. A composition as claimed in claim 25 in the form of a liquid drench or an oral or injectable formulation.
27. A composition as claimed in claim 25 in the form of an animal feedstuff or in the form of a premix or supplement for addition to animal feed.
28. Use of a compound of the formula I as claimed in any one of claims 1 to 11 and 14 to 22 in the treatment or prevention of parasitic infections in humans and animals.
29. A method of combating agricultural or horticultural pest infestations, which comprises applying an effective amount of a compound of the formula (I) as claimed in any one of claims 1 to 11 and 14 to 20 to the organism responsible for said infection or infestation or to the location thereof.
30. A commercial package containing, as active ingredient, a compound of the general formula (I) as claimed in any one of claims 1 to 11 and 14 to 22, together with instructions for its use for combating insect or parasite infections or infestations in humans or in animals or in agriculture or in horticulture.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB858518999A GB8518999D0 (en) | 1985-07-27 | 1985-07-27 | Antiparasitic agents |
| GB8518999 | 1985-07-27 | ||
| GB8520069 | 1985-08-09 | ||
| GB858520069A GB8520069D0 (en) | 1985-08-09 | 1985-08-09 | Anti-parasitic agents |
| GB868610063A GB8610063D0 (en) | 1986-04-24 | 1986-04-24 | Antiparasitic agents |
| GB8610063 | 1986-04-24 | ||
| GB868610862A GB8610862D0 (en) | 1986-05-02 | 1986-05-02 | Antiparasitic agents |
| GB8610862 | 1986-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1339480C true CA1339480C (en) | 1997-09-30 |
Family
ID=27449680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000514661A Expired - Lifetime CA1339480C (en) | 1985-07-27 | 1986-07-25 | Antiparasitic agents and process for their preparation |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US5089480A (en) |
| EP (1) | EP0214731B1 (en) |
| JP (1) | JPH0637501B2 (en) |
| CN (1) | CN1007266B (en) |
| AP (1) | AP37A (en) |
| AU (1) | AU572402B2 (en) |
| BG (1) | BG46601A3 (en) |
| CA (1) | CA1339480C (en) |
| CY (1) | CY1719A (en) |
| DE (1) | DE3676396D1 (en) |
| DK (1) | DK169036B1 (en) |
| ES (1) | ES8800986A1 (en) |
| FI (1) | FI87367C (en) |
| GR (1) | GR861965B (en) |
| HK (1) | HK65793A (en) |
| HU (1) | HU195856B (en) |
| IE (1) | IE58640B1 (en) |
| IL (1) | IL79523A (en) |
| LU (1) | LU88788I2 (en) |
| MA (1) | MA20746A1 (en) |
| NL (1) | NL950011I2 (en) |
| NO (2) | NO165881C (en) |
| NZ (1) | NZ216980A (en) |
| OA (1) | OA08370A (en) |
| PH (1) | PH23081A (en) |
| PL (1) | PL153429B1 (en) |
| PT (1) | PT83070B (en) |
| SK (1) | SK278513B6 (en) |
| SU (1) | SU1560059A3 (en) |
| UA (1) | UA6345A1 (en) |
| YU (1) | YU44294B (en) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BG44205A3 (en) * | 1984-09-14 | 1988-10-14 | Glaxo Group Ltd,Gb | Method for preparing of antibiotic s541 |
| AU596586B2 (en) * | 1985-04-30 | 1990-05-10 | American Cyanamid Company | Chemical derivatives of antibiotics S541 |
| EP0215654B1 (en) * | 1985-09-13 | 1995-03-15 | American Cyanamid Company | Macrolide antibiotics and their preparation |
| NZ219577A (en) * | 1986-03-12 | 1989-01-06 | Glaxo Group Ltd | Milbemycin derivatives and compositions |
| EP0254583B1 (en) * | 1986-07-24 | 1994-09-07 | Beecham Group Plc | Parasiticidal milbemycin derivatives, a process for their production, and compositions containing the same |
| EP0260537A1 (en) * | 1986-09-12 | 1988-03-23 | American Cyanamid Company | 13-Deoxy-23-oxo(keto) and 23-imino derivatives of 13-deoxy C-076-aglycone compounds |
| US5149832A (en) * | 1986-09-12 | 1992-09-22 | American Cyanamid Company | Mono and diacyl derivatives of ll-f28249 compounds |
| US4886828A (en) * | 1986-09-12 | 1989-12-12 | American Cyanamid Company | Δ22 -derivatives of LL-F28249 compounds |
| ES2055695T3 (en) * | 1986-09-12 | 1994-09-01 | American Cyanamid Co | DERIVATIVES 23-DESOXY OF COMPOUNDS LL-F28249. |
| US5019589A (en) * | 1986-09-12 | 1991-05-28 | American Cyanamid Company | Δ23 -LL-F28249 compounds |
| US5238848A (en) * | 1987-01-23 | 1993-08-24 | Pfizer Inc | Cultures for production of avermectins |
| ES2058244T3 (en) * | 1987-01-23 | 1994-11-01 | Pfizer | PROCEDURE FOR THE PRODUCTION OF AVERMECTINS AND CROPS FOR THE SAME. |
| IN167980B (en) * | 1987-01-23 | 1991-01-19 | Pfizer | |
| US5234831A (en) * | 1987-01-23 | 1993-08-10 | Pfizer Inc | Cultures for production of B avermectins |
| US5525506A (en) * | 1987-01-23 | 1996-06-11 | Pfizer Inc. | Process for production of avermectins and cultures therefor |
| US4886830A (en) * | 1987-03-06 | 1989-12-12 | American Cyanamid Company | Mono- and diepoxide derivatives of 23-deoxyl-LL-F28249 compounds |
| US4851428A (en) * | 1987-03-06 | 1989-07-25 | American Cyanamid Company | Mono- and diepoxide derivatives of Δ22-LL-F28249 compounds |
| US4956479A (en) * | 1987-03-06 | 1990-09-11 | American Cyanamid Company | 23-deoxy-27-chloro derivatives of LL-F28249 compounds |
| US4806527A (en) * | 1987-03-16 | 1989-02-21 | Merck & Co., Inc. | Avermectin derivatives |
| NZ225364A (en) * | 1987-07-20 | 1990-04-26 | Merck & Co Inc | 5,23-di-hydroxy 25-(4-methyl-hex-2-en-2-yl) milbemycin and parasiticidal compositions |
| JPS6431776A (en) * | 1987-07-28 | 1989-02-02 | Sankyo Co | Novel macrolide compound and production thereof |
| GB8721647D0 (en) * | 1987-09-15 | 1987-10-21 | Pfizer Ltd | Antiparasitic agents |
| US5240850A (en) * | 1987-10-23 | 1993-08-31 | Pfizer Inc. | Cultures for production of avermectin aglycones |
| ES2054822T3 (en) * | 1987-10-23 | 1994-08-16 | Pfizer | PROCEDURE FOR THE PRODUCTION OF AVERMECTIN AGLICONES AND THEIR CROPS. |
| DE3888936T2 (en) * | 1987-11-03 | 1994-07-21 | Beecham Group Plc | Intermediates for the production of macrolide antibiotics with an anthelmintic effect. |
| ATE87926T1 (en) * | 1987-11-09 | 1993-04-15 | Pfizer | ETHYLATED AVERMECTINS. |
| GB8726730D0 (en) * | 1987-11-14 | 1987-12-16 | Pfizer Ltd | Antiparasitic agents |
| GB8807280D0 (en) * | 1988-03-26 | 1988-04-27 | Pfizer Ltd | Antiparasitic agents |
| GB8809232D0 (en) * | 1988-04-19 | 1988-05-25 | Pfizer Ltd | Antiparasitic agents |
| GB8815967D0 (en) * | 1988-07-05 | 1988-08-10 | Pfizer Ltd | Antiparasitic agents |
| US5015662A (en) * | 1988-10-18 | 1991-05-14 | Merck & Co., Inc. | Anthelmintic bioconversion products |
| MA21697A1 (en) * | 1988-12-19 | 1990-07-01 | Dow Agrosciences Llc | MACROLIDE COMPOUNDS. |
| NZ231773A (en) * | 1988-12-23 | 1992-09-25 | Merck & Co Inc | Avermectin derivatives, preparation and parasiticidal pharmaceutical compositions thereof |
| US5015630A (en) * | 1989-01-19 | 1991-05-14 | Merck & Co., Inc. | 5-oxime avermectin derivatives |
| US4897383A (en) * | 1989-02-13 | 1990-01-30 | Merck & Co., Inc. | Avermectin derivatives |
| US6001822A (en) * | 1989-04-11 | 1999-12-14 | Pfizer Inc. | Antiparasitic formulations |
| US5057499A (en) * | 1989-06-02 | 1991-10-15 | Merck & Co. Inc. | Avermectin derivatives |
| US5030622A (en) * | 1989-06-02 | 1991-07-09 | Merck & Co., Inc. | Avermectin derivatives |
| US5023241A (en) * | 1989-07-31 | 1991-06-11 | Merck & Co., Inc. | Avermectin derivatives |
| EP0454820A4 (en) * | 1989-10-30 | 1992-03-11 | Eli Lilly And Company | A83543 recovery process |
| US5830875A (en) * | 1989-10-30 | 1998-11-03 | Merck & Co., Inc. | 24-and 25-substituted avermectin and milbemycin derivatives |
| US5188944A (en) * | 1990-06-22 | 1993-02-23 | Merck & Co., Inc. | Process for the glycosylation of avermectin agylcones |
| US5208222A (en) * | 1991-03-28 | 1993-05-04 | Merck & Co., Inc. | 4"-and 4'-alkylthio avermectin derivatives |
| US5240915A (en) * | 1991-10-15 | 1993-08-31 | Merck & Co., Inc. | Avermectin derivatives |
| AU660205B2 (en) * | 1991-12-23 | 1995-06-15 | Virbac, Inc | Systemic control of parasites |
| GB9201505D0 (en) * | 1992-01-24 | 1992-03-11 | Pfizer Ltd | Antiparasitic agents |
| GB9205007D0 (en) * | 1992-03-07 | 1992-04-22 | Pfizer Ltd | Antiparasitic agents |
| US6103504A (en) * | 1992-03-25 | 2000-08-15 | Pfizer Inc. | Process for production of avermectins and cultures therefor |
| US5241083A (en) * | 1992-07-01 | 1993-08-31 | Merck & Co., Inc. | Process for converting the 13-α-hydroxy group of avermectin aglycones |
| US5591606A (en) * | 1992-11-06 | 1997-01-07 | Dowelanco | Process for the production of A83543 compounds with Saccharopolyspora spinosa |
| WO1994012947A1 (en) * | 1992-11-20 | 1994-06-09 | British Technology Group Limited | Image reconstruction |
| US5292647A (en) * | 1992-11-30 | 1994-03-08 | Eli Lilly And Company | Strain of streptomyces for producing avermectins and processes therewith |
| US5411946A (en) * | 1993-02-24 | 1995-05-02 | Merck & Co., Inc. | Avermectin derivatives |
| ES2099604T3 (en) * | 1993-03-12 | 1997-05-16 | Dowelanco | NEW A83543 COMPOUNDS AND PROCEDURE FOR ITS PRODUCTION. |
| GB9315108D0 (en) * | 1993-07-21 | 1993-09-01 | Pfizer Ltd | Antiparasitic agents |
| ATE175240T1 (en) * | 1993-07-23 | 1999-01-15 | Pfizer | PROCESS FOR THE PRECIPITATION OF NATURAL AVERMECTINS AND FERMENTATION PROCESS FOR THE PRODUCTION OF THE SAME |
| DK0722453T3 (en) * | 1993-10-05 | 1999-12-27 | Pfizer | Process and antiparasitic intermediates for doramectin |
| TW327125B (en) * | 1994-02-07 | 1998-02-21 | Merck & Co Inc | Composition and method for protecting against pine exhausted |
| DE4427766A1 (en) * | 1994-08-05 | 1996-02-08 | Basf Ag | Process for the preparation of liquid crystalline mixtures |
| WO1996019920A1 (en) * | 1994-12-27 | 1996-07-04 | Pfizer Pharmaceuticals Inc. | Compositions for treating nematode infections in trees |
| US6001981A (en) * | 1996-06-13 | 1999-12-14 | Dow Agrosciences Llc | Synthetic modification of Spinosyn compounds |
| EP0959891A1 (en) * | 1996-07-30 | 1999-12-01 | Ashmont Holdings Limited | Anthelmintic formulations |
| AU4139797A (en) * | 1997-06-09 | 1998-12-30 | Nauchno-Proizvodstvennoye Obiedinenie "Farmbiomed" | (streptomyces avermitilis) strain, method for separating avermectin complexe s and preparations for protecting plants and animals |
| RU2138268C1 (en) * | 1997-09-22 | 1999-09-27 | Мосин Владимир Александрович | Agent suppressing proliferation and causing death of tumor cells and protecting normal cells |
| AP1060A (en) | 1998-01-02 | 2002-04-23 | Pfizer Prod Inc | Novel erythromycin derivatives. |
| GB9825402D0 (en) | 1998-11-19 | 1999-01-13 | Pfizer Ltd | Antiparasitic formulations |
| DE19913534A1 (en) * | 1999-03-25 | 2000-10-05 | Bayer Ag | Avermectin derivatives |
| US6787342B2 (en) | 2000-02-16 | 2004-09-07 | Merial Limited | Paste formulations |
| KR20020067781A (en) * | 2001-02-19 | 2002-08-24 | 주식회사 엘지씨아이 | Anthelmintic injectable composition containing ivermectin and process for preparation thereof |
| DK2347654T3 (en) | 2001-09-17 | 2019-04-23 | Elanco Us Inc | Formulation for the control of lice or ticks in cattle |
| JP4587488B2 (en) | 2004-03-02 | 2010-11-24 | 株式会社Ａｄｅｋａ | A synthetic resin composition containing a low basic hindered amine compound having a carbonate skeleton and a coating composition containing the same. |
| MX2007003378A (en) | 2004-09-23 | 2007-05-10 | Schering Plough Ltd | Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives. |
| WO2006055565A2 (en) * | 2004-11-19 | 2006-05-26 | Schering-Plough Ltd. | Control of parasites in animals by the use of parasiticidal 2-phenyl-3-(1h-pyrrol-2-yl) acrylonitrile derivatives |
| AR054380A1 (en) * | 2005-06-09 | 2007-06-20 | Schering Plough Ltd | PARASITES CONTROL IN ANIMALS WITH DERIVATIVES OF N- ((PHENYLOXY) PHENYL) -1,1,1-TRIFLUOROMETANSULFONAMIDE AND N- (PHENYLSULFANIL) PHENYL) -1,1,1-TRIFLUOROMETANSULFONAMIDE |
| US8119667B2 (en) * | 2005-12-29 | 2012-02-21 | Schering-Plough Animal Health Corporation | Carbonates of fenicol antibiotics |
| EP1849363A1 (en) * | 2006-03-09 | 2007-10-31 | Cheminova A/S | Synergistic combination of glutamate- and GABA-gated chloride agonist pesticide and at least one of Vitamin E or Niacin |
| US20070238700A1 (en) * | 2006-04-10 | 2007-10-11 | Winzenberg Kevin N | N-phenyl-1,1,1-trifluoromethanesulfonamide hydrazone derivative compounds and their usage in controlling parasites |
| CA2672795A1 (en) * | 2006-12-13 | 2008-06-26 | Schering-Plough Ltd. | Water-soluble prodrugs of chloramphenicol, thiamphenicol, and analogs thereof |
| EP2091909A1 (en) * | 2006-12-13 | 2009-08-26 | Schering-Plough Ltd. | Water-soluble prodrugs of florfenicol and its analogs |
| KR100831643B1 (en) * | 2007-04-10 | 2008-05-22 | 류충오 | Connection joint and composite drive shaft assembly having them |
| TWI430995B (en) | 2007-06-26 | 2014-03-21 | Du Pont | Naphthalene isoxazoline invertebrate pest control agents |
| BRPI0810929B8 (en) | 2007-06-27 | 2022-12-06 | Du Pont | use of a compound of formula 1 |
| TWI556741B (en) | 2007-08-17 | 2016-11-11 | 英特威特國際股份有限公司 | Isoxazoline compositions and their use as antiparasitics |
| TWI401023B (en) | 2008-02-06 | 2013-07-11 | Du Pont | Mesoionic pesticides |
| CA2732017A1 (en) * | 2008-07-30 | 2010-02-04 | Intervet International B.V. | Process for preparing oxazoline-protected aminodiol compounds useful as intermediates to florfenicol |
| JP5595412B2 (en) | 2008-12-04 | 2014-09-24 | メリアル リミテッド | Dimeric avermectin and milbemycin derivatives |
| JP2012517994A (en) | 2009-02-16 | 2012-08-09 | ファイザー・インク | High dose doramectin formulation |
| AU2010224918A1 (en) | 2009-03-17 | 2011-10-06 | Intervet International B.V. | Macrocyclic lactone drug delivery system |
| UA110924C2 (en) | 2009-08-05 | 2016-03-10 | Е. І. Дю Пон Де Немур Енд Компані | Mesoionic pesticides |
| UA107804C2 (en) | 2009-08-05 | 2015-02-25 | Du Pont | Mixtures of pesticides mezoionnyh |
| BR112012002524A2 (en) | 2009-08-05 | 2019-09-24 | Du Pont | "compound of formula, composition, composition for protecting an animal from an parasitic invertebrate pest, methods for controlling an invertebrate pest and treated seed" |
| BR112012002519A2 (en) | 2009-08-05 | 2019-09-24 | Du Pont | "mesoionic pesticides" |
| WO2011043962A2 (en) * | 2009-10-07 | 2011-04-14 | Wyeth Llc | Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof |
| US20120196821A1 (en) | 2009-10-19 | 2012-08-02 | Roger Mervyn Sargent | Method and formulation for the control of parasites |
| BR112012014933B1 (en) | 2009-12-17 | 2020-10-27 | Merial, Inc. | compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles |
| KR20130124458A (en) | 2010-05-27 | 2013-11-14 | 이 아이 듀폰 디 네모아 앤드 캄파니 | Crystalline form of 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-n-[2-0x0-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide |
| AR081970A1 (en) | 2010-06-24 | 2012-10-31 | Intervet Int Bv | INJECTABLE FORMULATION OF A MACROCICLIC AND LEVAMISOL LACTONE, FORMULATION AND VETERINARY USE |
| WO2012087630A1 (en) | 2010-12-20 | 2012-06-28 | E.I. Du Pont De Nemours And Company | Pyridine and pyrimidine compounds for controlling invertebrate |
| HUE036441T2 (en) | 2011-12-02 | 2018-07-30 | Merial Inc | Long-acting injectable moxidectin formulations and novel moxidectin crystal forms |
| WO2013158422A1 (en) | 2012-04-17 | 2013-10-24 | E. I. Du Pont De Nemours And Company | Heterocyclic compounds for controlling invertebrate pests |
| CN103356687B (en) * | 2012-10-19 | 2016-06-01 | 厦门大学 | The purposes of a kind of ivermectin and derivative thereof |
| EP2886640A1 (en) | 2013-12-18 | 2015-06-24 | Riga Technical University | Process for isolation of milbemycins A3 and A4 |
| KR101789736B1 (en) | 2017-08-30 | 2017-10-25 | 대한민국 | Composition containg ivermectin for Exterminating Clavinema mariae Infection |
| WO2022034226A1 (en) | 2020-08-14 | 2022-02-17 | Universidad De Navarra | Avermectin and milbemycin compositions for inhalation |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE434277B (en) * | 1976-04-19 | 1984-07-16 | Merck & Co Inc | SET TO MAKE NEW ANTIHELMINTICALLY EFFECTIVE ASSOCIATIONS BY CULTIVATING STREPTOMYCS AVERMITILIS |
| US4134973A (en) * | 1977-04-11 | 1979-01-16 | Merck & Co., Inc. | Carbohydrate derivatives of milbemycin and processes therefor |
| US4199569A (en) * | 1977-10-03 | 1980-04-22 | Merck & Co., Inc. | Selective hydrogenation products of C-076 compounds and derivatives thereof |
| PH15982A (en) * | 1977-10-03 | 1983-05-18 | Merck & Co Inc | Selective hydrogenation producta of c-076 compounds and derivatives thereof |
| US4171314A (en) * | 1977-12-19 | 1979-10-16 | Merck & Co., Inc. | 13-Halo and 13-deoxy C-076 compounds |
| PH16612A (en) * | 1977-12-19 | 1983-11-28 | Merck & Co Inc | 13-halo and 13-deoxy derivatives of c-076 compounds |
| US4200581A (en) * | 1978-08-04 | 1980-04-29 | Merck & Co., Inc. | Alkyl derivatives of C-076 compounds |
| US4429042A (en) * | 1978-09-08 | 1984-01-31 | Merck & Co., Inc. | Strain of Streptomyces for producing antiparasitic compounds |
| US4328335A (en) * | 1979-08-13 | 1982-05-04 | Merck & Co., Inc. | Process for the interconversion of C-076 compounds |
| US4285963A (en) * | 1980-08-07 | 1981-08-25 | Merck & Co., Inc. | Novel derivatives of C-076 compounds |
| US4378353A (en) * | 1981-02-17 | 1983-03-29 | Merck & Co., Inc. | Novel C-076 compounds |
| US4333925A (en) * | 1981-05-11 | 1982-06-08 | Merck & Co., Inc. | Derivatives of C-076 compounds |
| JPS5878594A (en) * | 1981-11-06 | 1983-05-12 | Sankyo Co Ltd | Preparation of antibiotic substance b-41d, e, and g |
| US4423209A (en) * | 1982-02-26 | 1983-12-27 | Merck & Co., Inc. | Processes for the interconversion of avermectin compounds |
| US4427663A (en) * | 1982-03-16 | 1984-01-24 | Merck & Co., Inc. | 4"-Keto-and 4"-amino-4"-deoxy avermectin compounds and substituted amino derivatives thereof |
| US4423204A (en) * | 1982-09-02 | 1983-12-27 | The Upjohn Company | Amorphous copolyamide from lactam, dicarboxylic acid and bisimidazoline |
| JPS5953403A (en) * | 1982-09-21 | 1984-03-28 | Sankyo Co Ltd | Miticidal composition |
| US4469682A (en) * | 1983-01-28 | 1984-09-04 | Merck & Co., Inc. | Avermectin and milbemycin phosphate esters, pharmaceutical compositions, and method of use |
| BG44205A3 (en) * | 1984-09-14 | 1988-10-14 | Glaxo Group Ltd,Gb | Method for preparing of antibiotic s541 |
| HUT39739A (en) * | 1984-12-04 | 1986-10-29 | Ciba Geigy Ag | Process for production of derivatives of 13,3-milbemycin and medical preparatives containing thereof |
| GB8502925D0 (en) * | 1985-02-05 | 1985-03-06 | Ici Plc | Macrocyclic lactones |
| AU596586B2 (en) * | 1985-04-30 | 1990-05-10 | American Cyanamid Company | Chemical derivatives of antibiotics S541 |
| NZ216908A (en) * | 1985-07-29 | 1989-06-28 | Merck & Co Inc | Avermectin derivatives |
| EP0215654B1 (en) * | 1985-09-13 | 1995-03-15 | American Cyanamid Company | Macrolide antibiotics and their preparation |
| EP0235085A1 (en) * | 1986-02-20 | 1987-09-02 | Ciba-Geigy Ag | 13-Beta-sugar derivatives of milbemycine, their preparation and use as ekto- and endo-parasitic agents for treatment of animals and plants |
| GB8606120D0 (en) * | 1986-03-12 | 1986-04-16 | Glaxo Group Ltd | Process |
| US4831016A (en) * | 1986-10-31 | 1989-05-16 | Merck & Co., Inc. | Reduced avermectin derivatives |
| GB8815967D0 (en) * | 1988-07-05 | 1988-08-10 | Pfizer Ltd | Antiparasitic agents |
| US5422349A (en) * | 1992-08-14 | 1995-06-06 | G. D. Seale & Co. | Morpholino-oxazinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension |
-
1986
- 1986-06-23 ES ES556466A patent/ES8800986A1/en not_active Expired
- 1986-07-22 DE DE8686305604T patent/DE3676396D1/en not_active Expired - Lifetime
- 1986-07-22 LU LU88788C patent/LU88788I2/en unknown
- 1986-07-22 EP EP86305604A patent/EP0214731B1/en not_active Expired - Lifetime
- 1986-07-24 BG BG75874A patent/BG46601A3/en unknown
- 1986-07-24 OA OA58911A patent/OA08370A/en unknown
- 1986-07-25 DK DK353486A patent/DK169036B1/en not_active IP Right Cessation
- 1986-07-25 YU YU1341/86A patent/YU44294B/en unknown
- 1986-07-25 NZ NZ216980A patent/NZ216980A/en unknown
- 1986-07-25 MA MA20974A patent/MA20746A1/en unknown
- 1986-07-25 GR GR861965A patent/GR861965B/en unknown
- 1986-07-25 FI FI863065A patent/FI87367C/en not_active IP Right Cessation
- 1986-07-25 CA CA000514661A patent/CA1339480C/en not_active Expired - Lifetime
- 1986-07-25 IL IL79523A patent/IL79523A/en not_active IP Right Cessation
- 1986-07-25 SU SU864027887A patent/SU1560059A3/en active
- 1986-07-25 PL PL1986260806A patent/PL153429B1/en unknown
- 1986-07-25 HU HU863097A patent/HU195856B/en unknown
- 1986-07-25 CN CN86105218A patent/CN1007266B/en not_active Expired
- 1986-07-25 PT PT83070A patent/PT83070B/en active IP Right Revival
- 1986-07-25 UA UA4027887A patent/UA6345A1/en unknown
- 1986-07-25 IE IE198386A patent/IE58640B1/en not_active IP Right Cessation
- 1986-07-25 NO NO863014A patent/NO165881C/en not_active IP Right Cessation
- 1986-07-25 AU AU60569/86A patent/AU572402B2/en not_active Expired
- 1986-07-28 PH PH34071A patent/PH23081A/en unknown
- 1986-07-28 JP JP61177473A patent/JPH0637501B2/en not_active Expired - Lifetime
- 1986-08-01 AP APAP/P/1986/000040A patent/AP37A/en active
-
1988
- 1988-01-11 US US07/142,888 patent/US5089480A/en not_active Expired - Lifetime
-
1991
- 1991-11-22 SK SK3543-91A patent/SK278513B6/en unknown
-
1993
- 1993-03-09 US US08/028,459 patent/US5451511A/en not_active Expired - Lifetime
- 1993-07-08 HK HK657/93A patent/HK65793A/en not_active IP Right Cessation
-
1994
- 1994-05-06 CY CY171994A patent/CY1719A/en unknown
-
1995
- 1995-09-26 NL NL950011C patent/NL950011I2/en unknown
- 1995-11-17 NO NO1995009C patent/NO1995009I1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1339480C (en) | Antiparasitic agents and process for their preparation | |
| US6362168B1 (en) | Antiparasitic agents | |
| EP0350187B1 (en) | Antiparasitic agents | |
| US4927847A (en) | Novel C.25 (substituted (2-propenyl))-milbemycins | |
| US5840704A (en) | Antiparasitic agents and process for their preparation | |
| AU673229B2 (en) | Antiparasitic agents | |
| KR890000405B1 (en) | Preparation process for derivative of avermectin and milbemycun | |
| WO1993018779A1 (en) | A strain of streptomyces avermitilis glycosylates avermectin compounds | |
| CA1340678C (en) | Antiparasitic avermectin derivatives | |
| US5312753A (en) | Strain of streptomyces avermitilis capable of glycosylating avermectin compounds at the 13- and 14A positions | |
| CS262673B2 (en) | Process for preparing new derivatives of avermectine | |
| DD253822A5 (en) | METHOD OF PRODUCING A NEW AVERMECTIN DERIVATIVE AGAINST PARASITES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |
Effective date: 20140930 |